Tabula Rasa HealthCare (TRHC) 10-Q 4 Nov 22 2022 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Oct. 15, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	001-37888
Entity Registrant Name	Tabula Rasa HealthCare, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	46-5726437
Entity Address, Address Line One	228 Strawbridge Drive, Suite 100
Entity Address, City or Town	Moorestown
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08057
City Area Code	866
Local Phone Number	648 - 2767
Title of 12(b) Security	Common Stock
Trading Symbol	TRHC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		27,124,287
Entity Central Index Key	0001651561
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Amendment Flag	false

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash	$ 80,783	$ 9,395
Restricted cash	7,389	6,038
Accounts receivable, net of allowance of $107 and $110, respectively	18,960	21,405
Inventories	5,735	5,444
Prepaid expenses	3,484	3,812
Client claims receivable	16,193	11,257
Other current assets	20,439	18,033
Current assets of discontinued operations	26,861	14,511
Total current assets	179,844	89,895
Contingent consideration receivable	7,000
Property and equipment, net	10,038	11,778
Operating lease right-of-use assets	14,069	16,323
Software development costs, net	32,606	29,254
Goodwill	115,323	115,323
Intangible assets, net	40,275	45,358
Other assets	4,691	3,929
Noncurrent assets of discontinued operations		187,558
Total assets	403,846	499,418
Current liabilities:
Current operating lease liabilities	3,195	3,275
Accounts payable	14,685	8,870
Client claims payable	9,537	8,398
Accrued expenses and other liabilities	59,507	40,997
Current liabilities of discontinued operations	11,132	12,380
Total current liabilities	98,056	73,920
Line of credit		29,500
Long-term debt, net of discount of $3,404 and $5,701, respectively	231,868	319,299
Long-term debt - related party, net of discount of $1,299 and $0, respectively	88,429
Noncurrent operating lease liabilities	13,223	15,792
Deferred income tax liability, net	889	1,402
Other long-term liabilities	3,032	176
Noncurrent liabilities of discontinued operations		3,573
Total liabilities	435,497	443,662
Commitments and contingencies (Note 15)
Stockholders' equity (deficit):
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding at September 30, 2022 and December 31, 2021
Common stock, $0.0001 par value; 100,000,000 shares authorized, 27,967,305 and 26,036,236 shares issued and 27,081,443 and 25,666,434 shares outstanding at September 30, 2022 and December 31, 2021, respectively	3	3
Treasury stock, at cost; 885,862 and 369,802 shares at September 30, 2022 and December 31, 2021, respectively	(3,350)	(4,292)
Additional paid-in capital	349,911	320,392
Accumulated deficit	(378,215)	(260,347)
Total stockholders' equity (deficit)	(31,651)	55,756
Total liabilities and stockholders' equity (deficit)	$ 403,846	$ 499,418

CONSOLIDATED BALANCE SHEETS (pa

CONSOLIDATED BALANCE SHEETS (parenthetical) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
CONSOLIDATED BALANCE SHEETS
Allowance for accounts receivable	$ 107	$ 110
Long-term debt, discount	3,404	5,701
Long-term debt - related party, discount	$ 1,299	$ 0
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	27,967,305	26,036,236
Common stock, shares outstanding	27,081,443	25,666,434
Treasury stock (in shares)	885,862	369,802

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue:
Total revenue	$ 77,101	$ 67,910	$ 216,808	$ 190,985
Cost of revenue, exclusive of depreciation and amortization shown below:
Total cost of revenue, exclusive of depreciation and amortization	60,235	51,215	169,587	142,814
Operating expenses:
Research and development	4,018	3,699	11,226	11,069
Sales and marketing	2,857	2,719	7,678	8,225
General and administrative	27,917	14,393	58,945	45,725
Long-lived asset impairment charge			4,062
Depreciation and amortization	5,723	5,328	16,954	15,109
Total operating expenses	40,515	26,139	98,865	80,128
Loss from operations	(23,649)	(9,444)	(51,644)	(31,957)
Other income (expense):
Interest expense, net	2,717	2,230	7,430	6,959
Other income	479		479
Total other expense, net	(2,238)	(2,230)	(6,951)	(6,959)
Loss from continuing operations before income taxes	(25,887)	(11,674)	(58,595)	(38,916)
Income tax (benefit) expense	(7)	82	368	284
Net loss from continuing operations	(25,880)	(11,756)	(58,963)	(39,200)
Net loss from discontinued operations, net of tax	(14,185)	(5,355)	(58,905)	(18,484)
Net loss	$ (40,065)	$ (17,111)	$ (117,868)	$ (57,684)
Net loss per share:
Net loss per share from continuing operations, basic (in dollars per share)	$ (1.07)	$ (0.50)	$ (2.45)	$ (1.68)
Net loss per share from discontinued operations, basic (in dollars per share)	(0.58)	(0.23)	(2.45)	(0.80)
Total net loss per share, basic (in dollars per share)	(1.65)	(0.73)	(4.90)	(2.48)
Net loss per share from continuing operations, diluted (in dollars per share)	(1.07)	(0.50)	(2.45)	(1.68)
Net loss per share from discontinued operations, diluted (in dollars per share)	(0.58)	(0.23)	(2.45)	(0.80)
Total net loss per share, diluted (in dollars per share)	$ (1.65)	$ (0.73)	$ (4.90)	$ (2.48)
Weighted average common shares outstanding:
Weighted average common shares outstanding, basic (in shares)	24,350,182	23,407,391	24,075,666	23,230,138
Weighted average common shares outstanding, diluted (in shares)	24,350,182	23,407,391	24,075,666	23,230,138
Product
Revenue:
Total revenue	$ 59,780	$ 50,321	$ 166,645	$ 139,021
Cost of revenue, exclusive of depreciation and amortization shown below:
Total cost of revenue, exclusive of depreciation and amortization	46,221	38,518	129,157	104,939
Service
Revenue:
Total revenue	17,321	17,589	50,163	51,964
Cost of revenue, exclusive of depreciation and amortization shown below:
Total cost of revenue, exclusive of depreciation and amortization	$ 14,014	$ 12,697	$ 40,430	$ 37,875

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands	Common Stock	Treasury Stock	Additional Paid-in Capital Cumulative Effect, Period of Adoption, Adjustment	Additional Paid-in Capital	Accumulated Deficit Cumulative Effect, Period of Adoption, Adjustment	Accumulated Deficit	Cumulative Effect, Period of Adoption, Adjustment	Total
Balance at beginning of period at Dec. 31, 2020	$ 2	$ (4,018)	$ (74,850)	$ 352,445	$ (1,392)	$ (179,900)	$ (76,242)	$ 168,529
Balance at beginning of period (in shares) at Dec. 31, 2020	24,222,674
Balance at beginning of period, treasury stock (in shares) at Dec. 31, 2020		(217,778)
Increase (Decrease) in Stockholders' Equity
Issuance of common stock awards (in shares)	1,416
Issuance of restricted stock (in shares)	629,088
Forfeitures of restricted shares (in shares)		(12,880)
Exercise of stock options, net of shares withheld		$ (274)		2,501				2,227
Exercise of stock options, net of shares withheld (in shares)	224,503	(6,218)
Stock-based compensation expense				8,602				8,602
Net loss						(19,492)		(19,492)
Balance at end of period at Mar. 31, 2021	$ 2	$ (4,292)		288,698		(200,784)		83,624
Balance at end of period (in shares) at Mar. 31, 2021	25,077,681
Balance at end of period, treasury stock (in shares) at Mar. 31, 2021		(236,876)
Balance at beginning of period at Dec. 31, 2020	$ 2	$ (4,018)	$ (74,850)	352,445	$ (1,392)	(179,900)	$ (76,242)	168,529
Balance at beginning of period (in shares) at Dec. 31, 2020	24,222,674
Balance at beginning of period, treasury stock (in shares) at Dec. 31, 2020		(217,778)
Increase (Decrease) in Stockholders' Equity
Net loss								(57,684)
Balance at end of period at Sep. 30, 2021	$ 2	$ (4,292)		310,514		(238,976)		67,248
Balance at end of period (in shares) at Sep. 30, 2021	25,323,087
Balance at end of period, treasury stock (in shares) at Sep. 30, 2021		(290,775)
Balance at beginning of period at Mar. 31, 2021	$ 2	$ (4,292)		288,698		(200,784)		83,624
Balance at beginning of period (in shares) at Mar. 31, 2021	25,077,681
Balance at beginning of period, treasury stock (in shares) at Mar. 31, 2021		(236,876)
Increase (Decrease) in Stockholders' Equity
Issuance of restricted stock (in shares)	120,598
Forfeitures of restricted shares (in shares)		(22,913)
Exercise of stock options, net of shares withheld				885				885
Exercise of stock options, net of shares withheld (in shares)	84,396
Stock-based compensation expense				12,349				12,349
Net loss						(21,081)		(21,081)
Balance at end of period at Jun. 30, 2021	$ 2	$ (4,292)		301,932		(221,865)		75,777
Balance at end of period (in shares) at Jun. 30, 2021	25,282,675
Balance at end of period, treasury stock (in shares) at Jun. 30, 2021		(259,789)
Increase (Decrease) in Stockholders' Equity
Issuance of restricted stock (in shares)	13,290
Forfeitures of restricted shares (in shares)		(30,986)
Exercise of stock options, net of shares withheld				571				571
Exercise of stock options, net of shares withheld (in shares)	27,122
Stock-based compensation expense				8,011				8,011
Net loss						(17,111)		(17,111)
Balance at end of period at Sep. 30, 2021	$ 2	$ (4,292)		310,514		(238,976)		67,248
Balance at end of period (in shares) at Sep. 30, 2021	25,323,087
Balance at end of period, treasury stock (in shares) at Sep. 30, 2021		(290,775)
Balance at beginning of period at Dec. 31, 2021	$ 3	$ (4,292)		320,392		(260,347)		$ 55,756
Balance at beginning of period (in shares) at Dec. 31, 2021	26,036,236
Balance at beginning of period, treasury stock (in shares) at Dec. 31, 2021		(369,802)						(369,802)
Increase (Decrease) in Stockholders' Equity
Issuance of common stock awards (in shares)	16,471
Issuance of restricted stock (in shares)	297,434
Forfeitures of restricted shares (in shares)		(138,882)
Exercise of stock options, net of shares withheld				60				$ 60
Exercise of stock options, net of shares withheld (in shares)	11,646
Stock-based compensation expense				8,609				8,609
Net loss						(28,193)		(28,193)
Balance at end of period at Mar. 31, 2022	$ 3	$ (4,292)		329,061		(288,540)		36,232
Balance at end of period (in shares) at Mar. 31, 2022	26,361,787
Balance at end of period, treasury stock (in shares) at Mar. 31, 2022		(508,684)
Balance at beginning of period at Dec. 31, 2021	$ 3	$ (4,292)		320,392		(260,347)		$ 55,756
Balance at beginning of period (in shares) at Dec. 31, 2021	26,036,236
Balance at beginning of period, treasury stock (in shares) at Dec. 31, 2021		(369,802)						(369,802)
Increase (Decrease) in Stockholders' Equity
Net loss								$ (117,868)
Balance at end of period at Sep. 30, 2022	$ 3	$ (3,350)		349,911		(378,215)		$ (31,651)
Balance at end of period (in shares) at Sep. 30, 2022	27,967,305
Balance at end of period, treasury stock (in shares) at Sep. 30, 2022		(885,862)						(885,862)
Balance at beginning of period at Mar. 31, 2022	$ 3	$ (4,292)		329,061		(288,540)		$ 36,232
Balance at beginning of period (in shares) at Mar. 31, 2022	26,361,787
Balance at beginning of period, treasury stock (in shares) at Mar. 31, 2022		(508,684)
Increase (Decrease) in Stockholders' Equity
Issuance of common stock awards (in shares)	12,262
Issuance of restricted stock (in shares)	424,540
Forfeitures of restricted shares (in shares)		(30,542)
Exercise of stock options, net of shares withheld				3				3
Exercise of stock options, net of shares withheld (in shares)	927	(109)
Stock-based compensation expense				6,692				6,692
Net loss						(49,610)		(49,610)
Balance at end of period at Jun. 30, 2022	$ 3	$ (4,292)		335,756		(338,150)		(6,683)
Balance at end of period (in shares) at Jun. 30, 2022	26,799,516
Balance at end of period, treasury stock (in shares) at Jun. 30, 2022		(539,335)
Increase (Decrease) in Stockholders' Equity
Issuance of common stock awards		$ 3,082		(3,082)
Issuance of common stock awards (in shares)		615,066
Issuance of restricted stock (in shares)	1,167,532
Forfeitures of restricted shares (in shares)		(507,299)
Exercise of stock options, net of shares withheld				1				1
Exercise of stock options, net of shares withheld (in shares)	257
Shares withheld for payment of employee taxes		$ (2,140)						(2,140)
Shares withheld for payment of employee taxes (in shares)		(454,294)
Stock-based compensation expense				17,236				17,236
Net loss						(40,065)		(40,065)
Balance at end of period at Sep. 30, 2022	$ 3	$ (3,350)		$ 349,911		$ (378,215)		$ (31,651)
Balance at end of period (in shares) at Sep. 30, 2022	27,967,305
Balance at end of period, treasury stock (in shares) at Sep. 30, 2022		(885,862)						(885,862)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands		9 Months Ended
		Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net loss		$ (117,868)	$ (57,684)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization		24,285	35,343
Amortization of deferred financing costs and debt discount		1,972	1,714
Deferred taxes		(513)	337
Stock-based compensation		32,537	28,962
Acquisition-related contingent consideration paid			(67)
Impairment charges		46,355
Loss on divestiture of business		2,879
Other noncash items		(9)	9
Changes in operating assets and liabilities, net of effect of divestiture:
Accounts receivable, net		5,107	789
Inventories		(291)	(866)
Prepaid expenses and other current assets		(1,375)	(6,084)
Client claims receivables		(4,936)	(872)
Other assets		(1,357)	(2,604)
Accounts payable		5,074	1,587
Accrued expenses and other liabilities		13,534	2,138
Client claims payables		1,139	423
Other long-term liabilities		3,220	(108)
Net cash provided by operating activities		9,753	3,017
Cash flows from investing activities:
Purchases of property and equipment		(1,021)	(1,611)
Software development costs		(23,860)	(22,649)
Proceeds from divestiture of business	[1]	118,561
Net cash provided by (used in) investing activities		93,680	(24,260)
Cash flows from financing activities:
Proceeds from exercise of stock options		64	3,683
Payments for employee taxes for shares withheld		(1,112)
Payments for debt financing costs		(350)	(8)
Borrowings on line of credit		27,700	17,500
Repayments of line of credit		(57,200)
Payment of acquisition-related notes payable			(13,000)
Payments of acquisition-related contingent consideration			(99)
Repayments of long-term debt and finance leases			(4)
Net cash (used in) provided by financing activities		(30,898)	8,072
Net increase (decrease) in cash and restricted cash		72,535	(13,171)
Cash and restricted cash, beginning of period		15,706	28,532
Cash and restricted cash, end of period	[2]	88,241	15,361
Supplemental disclosure of cash flow information:
Purchases of property and equipment and software development included in accounts payable and accrued expenses		1,082	370
Cash paid for interest		7,204	8,169
Cash paid for taxes		137	44
Interest costs capitalized to software development costs		257	$ 216
Employee taxes for shares withheld included in accrued expenses		$ 1,028
[1] The cash proceeds received from divestiture of business do not include $1,477 of additional consideration subsequently received by the Company in October 2022 due to customary post-closing adjustments or $3,000 of transaction costs incurred as of the sale date and expected to be paid in the fourth quarter of 2022. See Note 3 for additional information. The cash flows related to discontinued operations have not been segregated. Accordingly, the unaudited consolidated statements of cash flows include the results of continuing and discontinued operations. As a result of the divestiture, the changes in operating assets and liabilities for the nine months ended September 30, 2022 exclude changes related to the divested business. See Note 3 for discussion of discontinued operations and divestiture of business.

CONSOLIDATED STATEMENTS OF CA_2

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($) $ in Thousands		Sep. 30, 2022	Sep. 30, 2021
Reconciliation of cash and restricted cash:
Cash		$ 80,783	$ 10,757
Restricted cash		7,389	4,014
Cash from discontinued operations		69	590
Total cash and restricted cash	[1]	$ 88,241	$ 15,361
[1] The cash flows related to discontinued operations have not been segregated. Accordingly, the unaudited consolidated statements of cash flows include the results of continuing and discontinued operations. As a result of the divestiture, the changes in operating assets and liabilities for the nine months ended September 30, 2022 exclude changes related to the divested business. See Note 3 for discussion of discontinued operations and divestiture of business.

Nature of Business

Nature of Business	9 Months Ended
	Sep. 30, 2022
Nature of Business
Nature of Business	1. Nature of Business ​ Tabula Rasa HealthCare, Inc. (the “Company”) is a healthcare technology company advancing the safe use of medications by creating solutions designed to empower pharmacists, providers, and patients to optimize medication regimens, combating medication overload and reducing adverse drug events. The Company’s advanced proprietary technology solutions, including MedWise®, identify causes of and risks for medication-related problems so healthcare professionals can minimize harm and reduce medication-related risks. The Company’s software and services help improve patient outcomes and lower healthcare costs through reduced hospitalizations, emergency department visits, and healthcare utilization. The Company serves a number of different organizations within the healthcare industry, including health plans, and at-risk provider groups, the majority of which are organizations with Programs of All-Inclusive Care for the Elderly (“PACE”). ​

Basis of Presentation, Summary

Basis of Presentation, Summary of Significant Accounting Policies, and Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2022
Basis of Presentation, Summary of Significant Accounting Policies, and Recent Accounting Pronouncements
Basis of Presentation, Summary of Significant Accounting Policies, and Recent Accounting Pronouncements	2. Basis of Presentation, Summary of Significant Accounting Policies, and Recent Accounting Pronouncements ​ (a) Basis of Presentation ​ The accompanying unaudited consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. The unaudited interim consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring accruals and adjustments) necessary to present fairly the Company’s interim consolidated financial position for the periods indicated. The interim results for the three and nine months ended September 30, 2022 are not necessarily indicative of results to be expected for the year ending December 31, 2022, any other interim periods, or any future year or period. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K filed with the SEC on February 25, 2022 (the “2021 Form 10-K”). ​ Except as described below, there have been no material changes to the Company’s significant accounting policies described in the 2021 Form 10-K that have a material impact on the Company’s accompanying unaudited consolidated financial statements and related notes. ​ (b) Assets and Liabilities Held for Sale and Discontinued Operations ​ A long-lived asset (or disposal group) is classified as held for sale if its carrying amount will be recovered principally through a sale transaction rather than through continuing use and a sale is considered highly probable within a year. A long-lived asset (or disposal group) classified as held for sale is initially measured at the lower of its carrying amount or fair value less costs to sell. An impairment loss is recognized for any initial or subsequent write-down of the long-lived asset (or disposal group) to fair value less costs to sell. A gain or loss not previously recognized by the date of the sale of the long-lived asset (or disposal group) is recognized at the date of derecognition. ​ Long-lived assets (including those that are part of a disposal group) are not depreciated or amortized while they are classified as held for sale. Long-lived assets classified as held for sale and the assets of a disposal group classified as held for sale are presented separately from the other assets in the balance sheet. The liabilities of a disposal group classified as held for sale are presented separately from other liabilities in the balance sheet. ​ Unless otherwise noted, amounts and disclosures throughout the notes to the unaudited consolidated financial statements relate to the Company’s continuing operations. ​ Additional details surrounding the Company’s assets and liabilities held for sale and discontinued operations are included in Note 3. ​ (c) Cloud Computing Arrangements ​ Costs to implement cloud computing arrangements that are hosted by third-party vendors are capitalized when incurred during the application development phase. Capitalized implementation costs are amortized on a straight-line basis over the reasonably certain term of the hosting arrangement, beginning when the service is ready for its intended use. As of September 30, 2022 and December 31, 2021, capitalized implementation costs of $882 and $747, respectively, were included in prepaid expenses, and $1,276 and $0, respectively, were included in other assets on the Company’s consolidated balance sheets. Accumulated amortization for these arrangements was $554 and $398 as of September 30, 2022 and December 31, 2021, respectively. Amortization expense for the three months ended September 30, 2022 and 2021, was $51 and $53, respectively. Amortization expense for the nine months ended September 30, 2022 and 2021, was $156 and $155, respectively. ​ (d) Vendor Financing Arrangements ​ On February 24, 2022, the Company expanded its existing relationship with a third-party service provider for business process outsourcing and technology services for its third-party administration services and electronic health records solutions. As a result, the third-party provider hired approximately 180 employees from the Company, hired to fill existing open positions and will augment with additional resources to meet client demand. The agreement term is seven years and includes total estimated fees of $115,300. ​ The arrangement includes extended payment terms for cloud computing implementation costs, internally developed software support, and business process support. In order to determine the present value of the commitment, the Company used an imputed interest rate of 9.5%, which was reflective of its estimated uncollateralized borrowing rate at signing. As of September 30, 2022, the outstanding principal balance of the financing arrangement was $3,772 with an unamortized discount of $876, and was included in accrued expenses and other liabilities and other long-term liabilities on the Company’s consolidated balance sheet. Imputed interest expense from the arrangement was $53 and $89 for the three and nine months ended September 30, 2022, respectively. ​ (e) Concentrations of Credit Risk ​ The Company is subject to concentrations of credit risk related to cash, restricted cash, accounts receivable, and client claims receivable. While the Company maintains its cash and restricted cash with financial institutions with high credit ratings, it often maintains these deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any realized losses on cash or restricted cash to date. ​ The Company’s medication fulfillment services clients are sponsors of the federal Medicare Part D plan (prescription drug coverage plan) and, therefore, subject to the payment regulations established by the Centers for Medicare & Medicaid Services (“CMS”). Under CMS guidelines, Medicare Part D sponsors are required to remit payment for claims within 14 ​ The Company’s clients also include health plans and other healthcare providers. Credit associated with these accounts is extended based upon management’s evaluation of creditworthiness and is monitored on an on-going basis. ​ As of September 30, 2022 and December 31, 2021, no client represented more than 10% of net accounts receivable. ​ As of September 30, 2022 one client represented 21% of client claims receivable. As of December 31, 2021, two clients represented 13% and 11%, respectively, of client claims receivable. ​ One client accounted for 15% and 13% of total revenue for the three months ended September 30, 2022 and 2021, respectively, and 16% and 14% of total revenue for the nine months ended September 30, 2022 and 2021, respectively. ​ (f) Recent Accounting Pronouncement In October 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2021-08, Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”). ASU 2021-08 requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities from acquired contracts using the revenue recognition guidance under ASC Topic 606 (Revenue from Contracts with Customers) in order to align the recognition of a contract liability with the definition of performance obligation. This approach differs from the current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value. ASU 2021-08 is effective for financial statements issued for fiscal years beginning after December 15, 2022; early adoption is permitted. The Company plans to adopt ASU 2021-08 on January 1, 2023 and does not expect it to have a significant impact on the consolidated financial statements.

Discontinued Operations

Discontinued Operations	9 Months Ended
	Sep. 30, 2022
Discontinued Operations
Discontinued Operations	3. Discontinued Operations ​ ​ In February 2022, the Company announced plans to evaluate non-core assets, refocus its corporate strategy, and increase stockholder value, and the Company commenced a plan to sell the DoseMe business, which the Company acquired in January 2019. In March 2022, the Company completed its evaluation of additional divestiture opportunities and commenced plans to sell the SinfoníaRx and PrescribeWellness businesses, which were acquired in September 2017 and March 2019, respectively. As described below, the Company completed the sale of its unincorporated PrescribeWellness business division (the “PrescribeWellness Business”) in August 2022. ​ The DoseMe, SinfoníaRx, and PrescribeWellness businesses comprised the majority of the Company’s MedWise HealthCare segment. The Company’s completed sale of the PrescribeWellness Business and plan of sale with respect to DoseMe and SinfoníaRx represent a strategic business shift having a significant effect on the Company’s operations and financial results. As a result, the Company determined that these businesses met such requirements to be classified as held for sale and discontinued operations as of March 31, 2022 and continued to meet the requirements as of September 30, 2022. Accordingly, unless otherwise indicated, the accompanying consolidated financial statements have been recast for all periods presented to reflect the assets, liabilities, revenue, and expenses related to these businesses as discontinued operations. ​ Divestiture of Business ​ On August 1, 2022 (the “Sale Date”), the Company completed the sale of its PrescribeWellness Business, including the assets, properties, and rights that were primarily used or held for use in connection with the PrescribeWellness Business, as well as the KD Assets (as defined below) to Transaction Data Systems, Inc. (“TDS”). On the Sale Date, the Company also completed the acquisition of certain intellectual property from karmadata, Inc. (“KD”) that had historically been licensed to the Company, (the “KD Assets”). The KD Assets acquired were simultaneously transferred to TDS on the Sale Date. The purchase consideration included $125,000 in cash, subject to certain customary post-closing adjustments, of which $118,561 was paid directly to the Company and $5,900 was paid to KD on the Sale Date. In October 2022, TDS also paid the Company $1,477 for certain customary post-closing adjustments subsequent to the Sale Date. The Company is also entitled to receive up to $15,000 contingent consideration to be paid by TDS based upon the PrescribeWellness Business’s achievement of certain performance-based metrics during the fiscal years ending December 31, 2023 and 2024. The contingent consideration had an estimated fair value of $7,000 on the Sale Date. See Note 14 for additional discussion on the fair value assessment of the contingent consideration receivable. ​ In connection with the sale of the PrescribeWellness Business, the Company entered into a transition services agreement (“TSA)” with TDS pursuant to which the Company is providing services, including, but not limited to, business support services for the PrescribeWellness business after the sale through April 2023. The Company recognized $479 of income related to the TSA for the three and nine months ended September 2022, which is reported in other income on the Company’s consolidated statement of operations. ​ During the six months ended June 30, 2022, as a result of the Company’s intention to sell the PrescribeWellness Business, the Company prepared an impairment test on the related net assets held for sale. Using a market approach to determine fair value, the Company concluded that the carrying value of the net assets held for sale for the PrescribeWellness Business did not exceed its fair value, less costs to sell. As a result, the Company recorded goodwill impairment charges of $12,145 and impairment charges of $8,500 on net assets held for sale, summarized in the results of the PrescribeWellness business presented below. On August 1, 2022, the Company recorded an additional $2,879 for the final loss on the sale of the PrescribeWellness Business, resulting in an aggregate loss of $11,379 on the net assets sold for the nine months ended September 30, 2022. ​ The following table summarizes the net assets sold as finally reported on the sale date of August 1, 2022 and as of December 31, 2021, classified as discontinued operations on the consolidated balance sheets as of December 31, 2021: ​ ​ ​ ​ ​ ​ ​ August 1, ​ December 31, ​ 2022 2021 Accounts receivable, net $ 5,020 ​ ​ 8,002 Prepaid expenses and other assets ​ 1,751 ​ ​ 1,038 Property and equipment, net ​ 371 ​ ​ — Operating lease right-of-use assets ​ 1,252 ​ ​ — Software development costs, net ​ 14,536 ​ ​ — Goodwill ​ 35,314 ​ ​ — Intangible assets, net ​ 81,504 ​ ​ — Impairment of carrying value ​ (8,500) ​ ​ — Total current assets of discontinued operations $ 131,248 ​ $ 9,040 ​ ​ ​ ​ ​ ​ Property and equipment, net $ — ​ $ 412 Operating lease right-of-use assets ​ — ​ ​ 1,434 Software development costs, net ​ — ​ ​ 11,474 Goodwill ​ — ​ ​ 47,459 Intangible assets, net ​ — ​ ​ 84,617 Other assets ​ — ​ ​ 64 Total noncurrent assets of discontinued operations $ — ​ $ 145,460 ​ ​ ​ ​ ​ ​ Operating lease liabilities $ 1,086 ​ $ 620 Accounts payable ​ 491 ​ ​ 913 Accrued expenses and other liabilities ​ 2,754 ​ ​ 3,529 Total current liabilities of discontinued operations $ 4,331 ​ $ 5,062 ​ ​ ​ ​ ​ ​ Noncurrent operating lease liabilities $ — ​ $ 830 Other long-term liabilities ​ — ​ ​ 135 Total noncurrent liabilities of discontinued operations $ — ​ $ 965 ​ The following table summarizes the results of operations of the PrescribeWellness Business, which are included in loss from discontinued operations, net of tax in the consolidated statements of operations for the three and nine months ended September 30, 2022 and 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ September 30, ​ September 30, ​ 2022 2021 ​ 2022 2021 Revenue $ 2,537 ​ $ 10,533 ​ $ 19,306 ​ $ 27,629 Cost of revenue, exclusive of depreciation and amortization ​ 1,229 ​ ​ 3,426 ​ ​ 7,747 ​ ​ 9,883 Operating expenses ​ 2,336 ​ ​ 8,373 ​ ​ 14,930 ​ ​ 24,427 Impairment charges ​ — ​ ​ — ​ ​ 20,645 ​ ​ — Loss on disposal of business ​ 2,879 ​ ​ — ​ ​ 2,879 ​ ​ — Loss from discontinued operations before income taxes ​ (3,907) ​ ​ (1,266) ​ ​ (26,895) ​ ​ (6,681) Income tax (benefit) expense ​ (11) ​ ​ 12 ​ ​ (299) ​ ​ 66 Net loss from discontinued operations, net of tax $ (3,896) ​ $ (1,278) ​ $ (26,596) ​ $ (6,747) ​ The following table summarizes the significant operating non-cash items and investing activities of PrescribeWellness Business: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended ​ ​ September 30, ​ 2022 2021 Depreciation and amortization ​ $ 4,551 ​ $ 12,059 Impairment charges ​ ​ 20,645 ​ ​ — Stock-based compensation ​ ​ 1,697 ​ ​ 2,352 Loss on disposal of business ​ ​ 2,879 ​ ​ — Purchases of property and equipment ​ ​ (22) ​ ​ (305) Software development costs ​ ​ (4,443) ​ ​ (9,783) ​ Held for Sale ​ The Company considers the sale of the DoseMe and SinfoníaRx businesses to be highly probable within one year. During the three and nine months ended September 30, 2022, as a result of the Company’s intention to sell the DoseMe and SinfoníaRx businesses, the Company prepared an impairment test on the related net assets held for sale. Using a market approach to determine fair value, the Company concluded that the carrying values of the net assets held for sale for the SinfoníaRx and DoseMe businesses did not exceed their fair values, less costs to sell. As a result, the Company recorded goodwill impairment charges of $6,127 and $15,521 of impairment charges on the net assets held for sale related to the DoseMe and SinfoníaRx businesses for the nine months ended September 30, 2022. For the three months ended September 30, 2022, the Company recorded $5,845 of impairment charges on the net assets held for sale related to the DoseMe and SinfoníaRx businesses. No goodwill impairment charges related to the DoseMe and SinfoníaRx businesses were recorded for the three months ended September 30, 2022. ​ The following table s ummarizes the results of operations of the businesses, which are included in loss from discontinued operations, net of tax in the consolidated statements of operations for the three and nine months ended September 30, 2022 and 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ September 30, ​ September 30, ​ 2022 2021 ​ 2022 2021 Revenue $ 6,407 ​ $ 8,143 ​ $ 23,094 ​ $ 26,961 Cost of revenue, exclusive of depreciation and amortization ​ 7,055 ​ ​ 6,521 ​ ​ 20,479 ​ ​ 19,755 Operating expenses ​ 3,879 ​ ​ 5,659 ​ ​ 13,639 ​ ​ 18,827 Impairment charges ​ 5,845 ​ ​ — ​ ​ 21,648 ​ ​ — Loss from discontinued operations before income taxes ​ (10,372) ​ ​ (4,037) ​ ​ (32,672) ​ ​ (11,621) Income tax (benefit) expense ​ (83) ​ ​ 40 ​ ​ (363) ​ ​ 116 Net loss from discontinued operations, net of tax $ (10,289) ​ $ (4,077) ​ $ (32,309) ​ $ (11,737) ​ The following table summarizes the DoseMe and SinfoníaRx businesses’ current and noncurrent assets and liabilities classified as discontinued operations on the consolidated balance sheets as of September 30, 2022 and December 31, 2021: ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ 2022 2021 Cash $ 69 ​ $ 273 Accounts receivable, net ​ 4,964 ​ ​ 4,644 Prepaid expenses and other assets ​ 796 ​ ​ 554 Property and equipment, net ​ 1,349 ​ ​ — Operating lease right-of-use assets ​ 3,732 ​ ​ — Software development costs, net ​ 6,910 ​ ​ — Goodwill ​ 1,927 ​ ​ — Intangible assets, net ​ 22,635 ​ ​ — Impairment of carrying value ​ (15,521) ​ ​ — Total current assets of discontinued operations $ 26,861 ​ $ 5,471 ​ ​ ​ ​ ​ ​ Property and equipment, net $ — ​ $ 1,485 Operating lease right-of-use assets ​ — ​ ​ 3,296 Software development costs, net ​ — ​ ​ 4,466 Goodwill ​ — ​ ​ 8,053 Intangible assets, net ​ — ​ ​ 24,675 Other assets ​ — ​ ​ 123 Total noncurrent assets of discontinued operations $ — ​ $ 42,098 ​ ​ ​ ​ ​ ​ Operating lease liabilities $ 3,458 ​ $ 793 Accounts payable ​ 3,077 ​ ​ 3,395 Accrued expenses and other liabilities ​ 4,597 ​ ​ 3,130 Total current liabilities of discontinued operations $ 11,132 ​ $ 7,318 ​ ​ ​ ​ ​ ​ Noncurrent operating lease liabilities ​ — ​ $ 2,608 Other long-term liabilities ​ — ​ ​ — Total noncurrent liabilities of discontinued operations $ — ​ $ 2,608 The following table summarizes the DoseMe and SinfoníaRx businesses’ significant operating non-cash items and investing activities of discontinued operations: ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended ​ ​ September 30, ​ 2022 2021 Depreciation and amortization ​ $ 2,780 ​ $ 8,175 Impairment charges ​ ​ 21,648 ​ ​ — Stock-based compensation ​ ​ 2,667 ​ ​ 2,510 Purchases of property and equipment ​ ​ (50) ​ ​ (1,323) Software development costs ​ ​ (2,998) ​ ​ (6,155) ​

Revenue

Revenue	9 Months Ended
	Sep. 30, 2022
Revenue.
Revenue	4. Revenue ​ The Company generates the majority of its revenue from its CareVention HealthCare segment. ​ Client contracts generally have a term of one 0 ​ The Company does not disclose the amount of variable consideration that the Company expects to recognize in future periods as the variable consideration in the Company’s contracts is allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied promise to transfer a distinct good or service that forms part of a single performance obligation, and the terms of that variable consideration relate specifically to the Company’s efforts to transfer the distinct service, or to a specific outcome from transferring the distinct service. The Company’s contracts primarily include monthly fees associated with unspecified quantities of medications, members, claims, medication safety reviews, or user subscriptions that fluctuate throughout the contract. See below for a description of the Company’s revenues. ​ CareVention HealthCare ​ PACE Product Revenue ​ The Company provides medication fulfillment pharmacy services to PACE organizations. While the majority of medications are routinely filled in order to treat chronic conditions, the mix and quantity of medications can vary. Revenue from medication fulfillment services is generally billed monthly or weekly, depending on whether the PACE organization is contracted with a pharmacy benefit manager, and is recognized when medications are delivered and control has passed to the client. At the time of delivery, the Company has performed substantially all of its performance obligations under its client contracts. The Company does not experience a significant level of returns or reshipments. ​ PACE Solutions ​ The Company provides medication safety services and health plan management services to PACE organizations. These services primarily include medication reviews, risk adjustment services, third-party administration services, pharmacy benefit management (“PBM”) solutions, and electronic health records software. Revenue related to these services primarily consists of a fixed monthly fee assessed based on number of members served (“per member per month”), a fee for each claim adjudicated, and subscription fees. These fees are recognized when the Company satisfies its performance obligation to stand ready to provide PACE services, which occurs when the Company’s clients have access to the PACE services. The Company generally bills for PACE services on a monthly basis. ​ For client contracts for which the Company performs both medication fulfillment and PBM services, the Company recognizes revenue using the gross method at the contract price negotiated with its clients and when the Company has concluded it controls the prescription drug before it is transferred to the client plan members. The Company controls prescription drugs dispensed indirectly through its retail pharmacy network because it has separate contractual arrangements with those pharmacies, has discretion in setting the price for the transaction, and assumes primary responsibility for fulfilling the promise to provide prescription drugs to its client plan members while performing the related PBM services. These factors indicate that the Company is the principal and, as such, the Company recognizes the total prescription price contracted with clients in revenue. ​ MedWise HealthCare ​ Medication Safety Services ​ The Company provides medication safety services, which include identification of high-risk individuals, medication regimen reviews including patient and prescriber counseling, and targeted interventions to increase adherence and close gaps in care. Revenue related to these services primarily consists of per member per month fees and fees for each medication review and clinical assessment completed. Revenue is recognized when the Company satisfies its performance obligation to stand ready to provide medication safety services, which occurs when the Company’s clients have access to the medication safety services and when medication reviews and clinical assessments are completed. The Company generally bills for the medication reviews and clinical assessments when they are completed. The Company generally bills for the medication safety services on a monthly basis. ​ Software Subscription and Services ​ The Company provides software as a service (“SaaS”) solutions which allow for the identification of individuals with high medication-related risk and for optimizing medication therapy. Revenues related to these software services primarily consist of monthly subscription fees and are recognized monthly as the Company meets its performance obligation to provide access to the software. Revenue for implementation and set-up services is generally recognized over the contract term as the software services are provided. The Company generally bills for the software services on a monthly basis. ​ Disaggregation of Revenue ​ In the following table, revenue is disaggregated by operating segment. Substantially all of the Company’s revenue is recognized in the U.S. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ September 30, ​ September 30, ​ ​ ​ 2022 ​ ​ 2021 ​ ​ 2022 ​ ​ 2021 CareVention HealthCare: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ PACE product revenue ​ $ 59,780 ​ $ 50,321 ​ $ 166,645 ​ $ 139,021 PACE solutions ​ ​ 16,416 ​ ​ 14,707 ​ ​ 47,604 ​ ​ 42,973 ​ ​ $ 76,196 ​ $ 65,028 ​ $ 214,249 ​ $ 181,994 MedWise HealthCare: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Medication safety services ​ $ 843 ​ $ 2,820 ​ $ 2,336 ​ $ 8,817 Software subscription and services ​ ​ 62 ​ ​ 62 ​ ​ 223 ​ ​ 174 ​ ​ $ 905 ​ $ 2,882 ​ $ 2,559 ​ $ 8,991 Total revenue ​ $ 77,101 ​ $ 67,910 ​ $ 216,808 ​ $ 190,985 ​ Contract Balances ​ Assets and liabilities related to the Company’s contracts are reported on a contract-by-contract basis at the end of each reporting period. Contract balances consist of contract assets and contract liabilities. Contract assets are recorded when the right to consideration for services is conditional on something other than the passage of time. Contract assets relating to unbilled receivables are transferred to accounts receivable when the right to consideration becomes unconditional. Contract assets are classified as current or non-current based on the timing of the Company’s rights to the unconditional payments. Contract assets are generally classified as current and recorded within other current assets on the Company’s consolidated balance sheets. ​ Contract liabilities include advance customer payments and billings in excess of revenue recognized. The Company generally classifies contract liabilities in accrued expenses and other current liabilities and in other long-term liabilities on the Company’s consolidated balance sheets. The Company anticipates that it will satisfy most of its performance obligations associated with its contract liabilities within one year. ​ The following table provides information about the Company’s contract assets and contract liabilities from contracts with clients as of September 30, 2022 and December 31, 2021. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ ​ 2022 2021 Contract assets ​ $ 15,072 ​ $ 12,695 Contract liabilities ​ ​ 4,110 ​ ​ 2,191 ​ Significant changes in the contract assets and the contract liabilities balances during the period are as follows: ​ ​ ​ ​ ​ ​ ​ September 30, ​ ​ 2022 Contract assets: ​ ​ ​ Contract assets, beginning of period ​ $ 12,695 Decreases due to cash received ​ ​ (12,466) Changes to the contract assets at the beginning of the period as a result of changes in estimates ​ ​ 451 Changes during the year, net of reclassifications to receivables ​ ​ 14,392 Contract assets, end of period ​ $ 15,072 ​ ​ ​ ​ Contract liabilities: ​ ​ ​ Contract liabilities, beginning of period ​ $ 2,191 Revenue recognized that was included in the contract liabilities balance at the beginning of the period ​ ​ (1,903) Increases due to cash received, excluding amounts recognized as revenue during the year ​ ​ 3,822 Contract liabilities, end of period ​ $ 4,110 ​ During the nine months ended September 30, 2021, the Company recognized $1,404 of revenue that was included in the December 31, 2020 contract liability balance of $1,982.

Net Loss per Share

Net Loss per Share	9 Months Ended
	Sep. 30, 2022
Net Loss per Share
Net Loss per Share	5. Net Loss per Share ​ Basic and diluted net loss per share is computed by dividing net loss by the weighted average number of shares of common stock of the Company outstanding during the period. ​ The following table presents the calculation of basic and diluted net loss per share for the Company’s common stock: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ September 30, ​ September 30, ​ 2022 2021 2022 2021 Numerator (basic and diluted): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss from continuing operations ​ $ (25,880) ​ $ (11,756) ​ $ (58,963) ​ $ (39,200) Net loss from discontinued operations ​ ​ (14,185) ​ ​ (5,355) ​ ​ (58,905) ​ ​ (18,484) Net loss ​ $ (40,065) ​ $ (17,111) ​ $ (117,868) ​ $ (57,684) Denominator (basic and diluted): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average shares of common stock outstanding, basic and diluted ​ ​ 24,350,182 ​ ​ 23,407,391 ​ ​ 24,075,666 ​ ​ 23,230,138 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss per share from continuing operations, basic and diluted ​ $ (1.07) ​ $ (0.50) ​ $ (2.45) ​ $ (1.68) Net loss per share from discontinued operations, basic and diluted ​ ​ (0.58) ​ ​ (0.23) ​ ​ (2.45) ​ ​ (0.80) Total net loss per share, basic and diluted ​ $ (1.65) ​ $ (0.73) ​ $ (4.90) ​ $ (2.48) ​ The following potential common shares, presented based on amounts outstanding as of September 30, 2022 and 2021, were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect. ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ 2022 2021 Stock options to purchase common stock ​ 1,402,931 ​ 1,671,680 Unvested restricted stock and restricted stock units ​ 2,217,033 ​ 1,624,523 Common stock warrants ​ 4,646,393 ​ 4,646,393 Conversion of convertible senior subordinated notes ​ 4,646,393 ​ 4,646,393 ​ ​ 12,912,750 ​ 12,588,989 ​ For the three and nine months ended September 30, 2022 and 2021, shares related to the conversion of the convertible senior subordinated notes were included in the table above using the if-converted method. ​ For the three and nine months ended September 30, 2022, shares related to performance stock units were excluded from the table above, as the performance conditions were unmet as of September 30, 2022 (see Note 13).

Other Current Assets

Other Current Assets	9 Months Ended
	Sep. 30, 2022
Other Current Assets
Other Current Assets	6. Other Current Assets ​ As of September 30, 2022 and December 31, 2021, other current assets consisted of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2022 December 31, 2021 Contract assets ​ $ 15,072 ​ $ 12,695 Non-trade receivables ​ ​ 1,235 ​ ​ 3,289 Divestiture related consideration receivables ​ ​ 1,477 ​ ​ — Other ​ ​ 2,655 ​ ​ 2,049 Total other current assets ​ $ 20,439 ​ $ 18,033 ​

Property and Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2022
Property and Equipment.
Property and Equipment	7. Property and Equipment ​ Accumulated depreciation was $18,890 and $17,427 as of September 30, 2022 and December 31, 2021, respectively. Depreciation expense on property and equipment for the three months ended September 30, 2022 and 2021 was $801 and $825, respectively. Depreciation expense on property and equipment for the nine months ended September 30, 2022 and 2021 was $2,862 and $2,672, respectively.

Software Development Costs

Software Development Costs	9 Months Ended
	Sep. 30, 2022
Software Development Costs
Software Development Costs	8. Software Development Costs ​ The Company capitalizes certain costs incurred in connection with obtaining or developing its proprietary software platforms, which support its product and service contracts. These costs include third-party contractors and payroll for employees directly involved with the software development, including external direct costs of material and services, and interest expense related to the borrowings attributable to software development. As of September 30, 2022 and December 31, 2021, capitalized software costs consisted of the following: ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2022 December 31, 2021 Software development costs $ 51,305 ​ $ 49,481 Less: accumulated amortization ​ (18,699) ​ ​ (20,227) Software development costs, net $ 32,606 ​ $ 29,254 ​ ​ ​ ​ ​ ​ Capitalized software development costs included above not yet subject to amortization $ 4,505 ​ $ 5,328 ​ Amortization expense for the three months ended September 30, 2022 and 2021 was $3,224 and $2,579, respectively. Amortization expense for the nine months ended September 30, 2022 and 2021 was $9,005 and $6,682, respectively. ​ During the first quarter of 2022, the Company became aware of changes in circumstances impacting the future functionality of certain capitalized software development costs in the MedWise HealthCare segment and evaluated the recoverability of the related long-lived assets by comparing their carrying amount to the future net undiscounted cash flows expected to be generated by the assets to determine if the carrying value was not recoverable. The recoverability test indicated that certain capitalized software development costs were impaired and, as a result, the Company used an income approach to measure the fair value of the assets and recognized non-cash impairment charges of $4,062 for the nine months ended September 30, 2022. There were no identified circumstances that would impact the future functionality of capitalized software development costs during the three months ended September 30, 2022.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets
Goodwill and Intangible Assets	9. Goodwill and Intangible Assets ​ The Company’s goodwill as of September 30, 2022 and December 31, 2021 was $115,323, which relates to the Company’s CareVention HealthCare segment. ​ During the first and second quarters of 2022, the Company experienced a sustained decline in the market price of its common stock and determined that an indicator of impairment was present. The Company performed a quantitative goodwill impairment assessment as of June 30, 2022, estimating the fair value of the Company’s reporting unit using a market approach. Based on the analysis performed, the Company determined that the estimated fair value of the Company’s reporting unit exceeded its carrying value, and, as a result, goodwill was not impaired as of June 30, 2022. No indicators of impairment were identified for the three months ended September 30, 2022. ​ Intangible assets consisted of the following as of September 30, 2022 and December 31, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortization Period ​ ​ ​ ​ Accumulated ​ Intangible ​ (in years) Gross Value Amortization Assets, net September 30, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Trade names ​ 2.6 ​ $ 1,340 ​ $ (982) ​ $ 358 Client relationships ​ 11.7 ​ ​ 51,264 ​ ​ (14,438) ​ ​ 36,826 Non-competition agreements ​ 5.0 ​ ​ 1,640 ​ ​ (1,221) ​ ​ 419 Developed technology ​ 6.2 ​ ​ 14,720 ​ ​ (12,076) ​ ​ 2,644 Domain name ​ 10.0 ​ ​ 59 ​ ​ (31) ​ ​ 28 Total intangible assets ​ ​ ​ $ 69,023 ​ $ (28,748) ​ $ 40,275 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortization Period ​ ​ ​ ​ Accumulated ​ Intangible ​ (in years) Gross Value Amortization Assets, net December 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Trade names ​ 2.9 ​ $ 1,340 ​ $ (853) ​ $ 487 Client relationships ​ 11.7 ​ ​ 51,264 ​ ​ (11,042) ​ ​ 40,222 Non-competition agreements ​ 5.0 ​ ​ 1,640 ​ ​ (975) ​ ​ 665 Developed technology ​ 6.2 ​ ​ 14,720 ​ ​ (10,768) ​ ​ 3,952 Domain name ​ 10.0 ​ ​ 59 ​ ​ (27) ​ ​ 32 Total intangible assets ​ ​ ​ $ 69,023 ​ $ (23,665) ​ $ 45,358 ​ Amortization expense for intangible assets for the three months ended September 30, 2022 and 2021 was $1,694 and $1,907, respectively. Amortization expense for intangible assets for the nine months ended September 30, 2022 and 2021 was $5,083 and $5,738, respectively. ​ The estimated amortization expense for the remainder of 2022 and each of the next five years and thereafter is as follows: ​ ​ ​ ​ ​ Years Ending December 31, ​ ​ 2022 (October 1 – December 31) ​ $ 1,669 2023 ​ ​ 6,162 2024 ​ ​ 4,684 2025 ​ ​ 4,466 2026 ​ ​ 4,338 2027 ​ ​ 4,271 Thereafter ​ ​ 14,685 Total estimated amortization expense ​ $ 40,275 ​

Accrued Expenses and Other Liab

Accrued Expenses and Other Liabilities	9 Months Ended
	Sep. 30, 2022
Accrued Expenses and Other Liabilities
Accrued Expenses and Other Liabilities	10. Accrued Expenses and Other Liabilities ​ As of September 30, 2022 and December 31, 2021, accrued expenses and other liabilities consisted of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2022 December 31, 2021 Employee related expenses ​ $ 8,961 ​ $ 8,595 Contract liability ​ ​ 3,864 ​ ​ 2,015 Customer deposits ​ ​ 903 ​ ​ 904 Client funds obligations* ​ ​ 7,389 ​ ​ 6,038 Contract labor ​ ​ 2,852 ​ ​ 838 Divestiture closing fees ​ ​ 3,000 ​ ​ — Interest ​ ​ 711 ​ ​ 2,281 Vendor financing arrangements ​ ​ 176 ​ ​ — Professional fees ​ ​ 2,161 ​ ​ 1,327 Consideration payable to customer ​ ​ 24,500 ​ ​ 15,971 Income and non-income taxes payable ​ ​ 95 ​ ​ 15 Other expenses ​ ​ 4,895 ​ ​ 3,013 Total accrued expenses and other liabilities ​ $ 59,507 ​ $ 40,997 ​ *This amount represents client funds held by the Company, with an offsetting amount included in restricted cash.

Line of Credit and Long-Term De

Line of Credit and Long-Term Debt	9 Months Ended
	Sep. 30, 2022
Lines of Credit and Long-Term Debt
Line of Credit and Long-Term Debt	11. Line of Credit and Long-Term Debt ​ (a) Line of Credit ​ On December 18, 2020, the Company and its subsidiaries entered into a Loan and Security Agreement (the “2020 Credit Facility”), with Western Alliance Bank (“WAB”). The 2020 Credit Facility provided for a $120,000 secured revolving credit facility, with a $1,000 sublimit for cash management services and letters of credit and foreign exchange transactions. ​ Amounts under the 2020 Credit Facility could be borrowed, repaid, and re-borrowed from time to time until the maturity date on May 16, 2025, and were permitted to be used for, among other things, working capital and other general corporate purposes. Loans under the 2020 Credit Facility bore interest at a rate equal to the LIBOR rate plus 3.25%. The obligations under the 2020 Credit Facility were secured by all of the assets of the borrowers, subject to certain exceptions and exclusions as set forth in the 2020 Credit Facility. The 2020 Credit Facility was subject to a commitment fee of 0.50% of the total commitment amount payable on the closing date, and 0.25% of the total commitment amount payable on each anniversary thereafter. Additionally, the 2020 Credit Facility was subject to an unused line fee. ​ On August 1, 2022, the Company entered into a payoff letter with WAB with respect to the 2020 Credit Facility, pursuant to which the Company voluntarily elected to pay all amounts outstanding, including principal and interest, under the 2020 Credit Facility and related loan documents (the “Pay Off”) using cash on hand and proceeds from the sale of the PrescribeWellness Business. Accordingly, the Company paid a total of $57,406 to WAB for the Pay Off, and terminated the 2020 Credit Facility and related loan documents (the “Termination”). The Company did not incur any prepayment or early termination penalties in connection with either the Pay Off or the Termination. Upon the Termination and in connection with the Pay Off, all security interests and pledges granted to the secured parties thereunder were terminated and released. ​ Interest expense on the 2020 Credit Facility was $266 and $1,363 for the three and nine months ended September 30, 2022, respectively. Interest expense on the 2020 Credit Facility was $314 and $842 for the three and nine months ended September 30, 2021, respectively. ​ In connection with the 2020 Credit Facility, the Company recorded deferred financing costs of $1,534. The Company amortized the associated deferred financing costs to interest expense using the effective-interest method over the term of the agreement. On August 1, 2022, in connection with the Termination, the remaining balance of deferred financing costs was amortized to interest expense. The Company amortized $698 and $973 to interest expense for the three and nine months ended September 30, 2022, respectively, for deferred financing costs. The Company amortized $136 and $404 to interest expense during the three and nine months ended September 30, 2021, respectively, for deferred financing costs. ​ (b) Convertible Senior Subordinated Notes ​ On February 12, 2019, the Company issued and sold an aggregate principal amount of $325,000 of 1.75% convertible senior subordinated notes (the “2026 Notes”) in a private placement pursuant to Rule 144A under the Securities Act of 1933, as amended. The 2026 Notes bear interest at a rate of 1.75% per year, payable semiannually in arrears on February 15 and August 15 of each year, beginning on August 15, 2019. The 2026 Notes will mature on February 15, 2026, unless earlier converted or repurchased. The initial conversion rate for the notes is 14.2966 shares of the Company’s common stock per $1 principal amount of the 2026 Notes. This conversion rate is equal to an initial conversion price of approximately $69.95 per share of the Company’s common stock. ​ Holders may convert all or any portion of their 2026 Notes at any time prior to the close of business on the business day immediately preceding August 15, 2025 only under the following circumstances: (1) during any calendar quarter commencing after March 31, 2019 (and only during such calendar quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2) during the five business day period after any five consecutive trading day period (the measurement period) in which the trading price (as defined in the indenture governing the 2026 Notes) per $1 principal amount of 2026 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate on each such trading day; or (3) upon the occurrence of specified corporate events, including certain distributions, the occurrence of a fundamental change or make-whole fundamental change (as defined in the indenture governing the 2026 Notes) or a transaction resulting in the Company’s common stock converting into other securities or property or assets. On or after August 15, 2025 until the close of business on the first scheduled trading day immediately preceding the maturity date, a holder may convert all or any portion of its 2026 Notes regardless of the foregoing circumstances. Upon conversion, the Company will pay or deliver shares of our common stock, cash or a combination thereof at the Company’s option. As of September 30, 2022, none of the conditions allowing holders of the 2026 Notes to convert had been met. Debt issuance costs related to the 2026 Notes of $9,372 are being amortized to interest expense using the effective interest method over the contractual term, resulting in an effective interest rate of 2.20%. ​ During the three months ended September 30, 2022, the Company recognized $1,757 of interest expense related to the 2026 Notes, of which $1,422 was paid or accrued and $335 was non-cash accretion of the debt discounts recorded. During the nine months ended September 30, 2022, the Company recognized $5,265 of interest expense related to the 2026 Notes, of which $4,266 was paid or accrued and $999 was non-cash accretion of the debt discounts recorded. ​ During the three months ended September 30, 2021, the Company recognized $1,750 of interest expense related to the 2026 Notes, of which $1,423 was paid or accrued, and $327 was non-cash accretion of the debt discounts recorded. During the nine months ended September 30, 2021, the Company recognized $5,243 of interest expense related to the 2026 Notes, of which $4,266 was paid or accrued, and $977 was non-cash accretion of the debt discounts recorded. In addition, unpaid additional interest payable as a result of the failure to remove the restrictive legend on the 2026 Notes had accrued on the 2026 Notes from and including February 17, 2020, but ceased accruing on February 16, 2021 as a result of the restrictive legend being removed. The Company recorded $212 of additional interest expense for the nine months ended September 30, 2021. ​ As of September 30, 2022, total accrued interest payable related to the 2026 Notes was $711, which is included in accrued expenses and other liabilities on the consolidated balance sheets. The 2026 Notes have a carrying value of $320,297 as of September 30, 2022. The 2026 Notes are classified as long-term debt on the Company’s consolidated balance sheets, and will be until such 2026 Notes are within one year of maturity. ​ (c) Convertible Note Hedge and Warrant Transactions ​ In connection with the offering of the 2026 Notes, the Company entered into convertible note hedge transactions with affiliates of certain of the initial purchasers (the “option counterparties”) of the 2026 Notes pursuant to the terms of call option confirmations. The Company has the option to purchase a total of 4,646,393 shares of its common stock at a price of approximately $69.95 per share. The total premiums paid for the note hedges were $101,660. The Company also entered into warrant transactions with the option counterparties whereby they have the option to purchase 4,646,393 shares of the Company’s common stock at a price of $105.58 per share. The Company received $65,910 in cash proceeds from the sale of the warrants. As these instruments are considered indexed to the Company's own stock and are considered equity classified, the convertible note hedges and warrants are recorded in stockholders’ equity, are not accounted for as derivatives and are not remeasured each reporting period. The net costs incurred in connection with the convertible note hedge and warrant transactions were recorded as a reduction to additional paid-in capital on the Company’s consolidated balance sheets. ​ The convertible note hedge transactions are expected generally to reduce the potential dilution to the Company’s common stock upon conversion of the 2026 Notes and/or offset any potential cash payments the Company is required to make in excess of the principal amount of converted 2026 Notes, as the case may be. The warrant transactions could separately have a dilutive effect on the Company’s common stock to the extent that the market price per share of the Company’s common stock exceeds the strike price of the warrants. ​ As of September 30, 2022, no warrants have been exercised and all warrants to purchase shares of the Company’s common stock were outstanding. ​ (d) Long-Term Debt ​ The following table represents the total long-term debt obligations of the Company at September 30, 2022 and December 31, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2022 December 31, 2021 Convertible senior subordinated notes ​ $ 235,272 ​ $ 325,000 Convertible senior subordinated notes - related party ​ ​ 89,728 ​ ​ — Unamortized discount, including debt issuance costs, on convertible senior subordinated notes ​ ​ (4,703) ​ ​ (5,701) Total long-term debt, net ​ $ 320,297 ​ $ 319,299 ​

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2022
Income Taxes
Income Taxes	12. Income Taxes ​ For the three months ended September 30, 2022 and 2021, the Company recorded income tax benefit of $7 and income tax expense of $82, respectively, which resulted in effective tax rates of 0.0% and (0.7)%, respectively. ​ For the nine months ended September 30, 2022 and 2021, the Company recorded income tax expense of $368 and $284, respectively, which resulted in effective tax rates of (0.6)% and (0.7)%, respectively. ​ The effective tax rates differ from the U.S. statutory tax rate primarily due to the full valuation allowance recorded that is currently limiting the realizability of the Company’s net deferred tax assets as of the end of the periods presented. Accordingly, the tax benefit was limited due to unbenefited losses in the three and nine months ended September 30, 2022 and 2021, respectively. ​ On February 12, 2021, the Company received a private letter ruling from the Internal Revenue Service, which determined, based on information submitted and representations made by the Company, that the Company met the requirements to deduct the interest expense resulting from the amortization of the debt discount associated with the 2026 Notes. As a result, the Company recorded a deferred tax asset of $26,313 and a corresponding $26,313 increase to its valuation allowance.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2022
Stock-Based Compensation
Stock-Based Compensation	13. Stock-Based Compensation ​ In September 2016, the Company adopted the 2016 Equity Compensation Plan ( ​ ​ Restricted Common Stock and Restricted Stock Units ​ The Company issues restricted stock awards and restricted stock units pursuant to the 2016 Plan to employees and non-employee directors. Restricted stock awards and restricted stock units generally vest over a one ​ The following table summarizes the aggregate restricted stock award activity, inclusive of performance based restricted stock awards, and restricted stock unit activity under the 2016 Plan for the nine months ended September 30, 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ average ​ ​ Number ​ grant-date ​ of shares fair value Outstanding at December 31, 2021 ​ 2,196,566 ​ $ 40.19 Granted ​ 1,935,883 ​ ​ 4.44 Vested ​ (1,224,471) ​ ​ 34.32 Forfeited ​ (676,723) ​ ​ 16.40 Outstanding at September 30, 2022 ​ 2,231,255 ​ $ 19.61 ​ The table above includes 14,222 restricted stock units which had vested but had not been issued as of September 30, 2022. ​ For the three months ended September 30, 2022 and 2021, an aggregate of $13,061 and $6,447 of expense, respectively, was recognized related to restricted stock awards and restricted stock units, excluding performance-based restricted stock awards described below. ​ For the nine months ended September 30, 2022 and 2021, an aggregate of $26,129 and $22,846 of expense, respectively, was recognized related to restricted stock awards and restricted stock units, excluding performance-based restricted stock awards as described below. As of September 30, 2022, there was unrecognized compensation expense of $30,976 related to unvested restricted stock awards and unvested restricted stock units, excluding performance-based restricted stock awards described below, under the 2016 Plan, which is expected to be recognized over a weighted average period of 2.4 years. ​ Expense related to restricted stock awards for the three and nine months ended September 30, 2022 includes $8,143 for the accelerated vesting of unvested shares of restricted stock related to separation agreements with two retired named executive officers. See Note 17 for additional information. ​ Performance-Based Equity Awards ​ On October 29, 2020, pursuant to the 2016 Plan, the Board approved grants totaling 26,400 shares of restricted stock to certain employees, of which 1,400 expired on April 30, 2021 and 12,500 expired on December 31, 2021. The remaining 12,500 shares fully vested subject to the achievement of certain milestones on December 31, 2021. The awards had a grant-date fair value of $35.95 per share based on the Company’s closing stock price on the grant date. Stock-based compensation costs associated with these grants were recognized over the service period based upon the Company’s assessment of the probability that the performance conditions would be achieved. The Company recognized $194 and $556 of stock-based compensation expense related to these grants for the three and nine months ended September 30, 2021, respectively. ​ On April 27, 2021, pursuant to the 2016 Plan, the Board approved awards of performance stock units to certain employees. Each award reflects a target number of shares (“Target 2021 Shares”) that may be issued to the award recipient. The awards are earned upon the Company’s achievement of certain revenue performance targets during the three-year performance period ending December 31, 2023. Depending on the results achieved during the performance period, the actual number of shares that a grant recipient may receive at the end of the performance period may range from 0% to 200% of the Target 2021 Shares granted. The performance stock unit awards have a grant-date fair value of $44.13 per share based on the Company’s closing stock price on the grant date. Stock-based compensation costs associated with these grants are recognized over the performance period based upon the Company’s assessment of the probability that the performance targets will be achieved. The Company did not recognize any stock-based compensation expense related to the performance stock units for the three and nine months ended September 30, 2022, as the achievement of the underlying performance targets was considered unlikely. During the nine months ended September 30, 2022, 47,175 performance stock units expired. As of September 30, 2022, the number of Target 2021 Shares was 45,550 shares. As of September 30, 2022, the maximum number of achievable performance stock units was 91,100 and the maximum unrecognized compensation expense was $4,020. ​ On August 22, 2022, pursuant to the 2016 Plan, the Board approved awards of performance stock units to certain executives. Each award reflects a target number of shares (“Target 2022 Shares”) that may be issued to the award recipient. The awards are earned upon the Company’s achievement of certain market performance targets during the three-year performance period ending December 31, 2024. Depending on the results achieved during the performance period, the actual number of shares that a grant recipient may receive at the end of the performance period may range from 0% to 200% of the Target 2022 Shares granted. The performance stock unit awards have a grant-date fair value of $4.38 per share based on the fair value of the Company’s stock price at grant date and the expected vesting units, taking into consideration the possibilities of all possible performance achievement levels. Stock-based compensation costs associated with these grants are recognized over the performance period. The Company recognized $69 of stock-based compensation expense related to the performance stock units for the three and nine months ended September 30, 2022. As of September 30, 2022, the number of Target 2022 Shares was 350,000 shares. As of September 30, 2022, the maximum number of achievable performance stock units was 700,000 and the remaining unrecognized compensation expense was $1,463. ​ Other Stock Awards ​ During the first quarter of 2021, the Board approved the grant of stock awards to certain non-employee directors and to a consultant pursuant to the 2016 Plan. The awards provided for the issuance of 1,416 shares of the Company’s common stock, which immediately vested on the grant date. These grants had a weighted average grant-date fair value of $40.85 per share. For the nine months ended September 30, 2021, the Company recorded $58 of expense related to these stock awards. ​ During the first quarter of 2022, the Board approved grants of stock awards to certain non-employee directors and employees pursuant to the 2016 Plan. The awards provided for the issuance of 16,471 shares of the Company’s common stock, which immediately vested on the grant date. These grants had a weighted average grant-date fair value of $5.57 per share. For the nine months ended September 30, 2022, the Company recorded $92 of expense related to these stock awards. ​ During the second quarter of 2022, the Board approved grants of stock awards to certain non-employee directors pursuant to the 2016 Plan. The awards provided for the issuance of 12,262 shares of the Company’s common stock, which immediately vested on the grant date. These grants had a weighted average grant-date fair value of $3.64 per share. For the nine months ended September 30, 2022, the Company recorded $45 of expense related to these stock awards. ​ During the third quarter of 2022, the Board approved grants of stock awards to certain employees pursuant to the 2016 Plan. The awards provided for the issuance of 615,066 shares of the Company’s common stock, which immediately vested on the grant date. These grants had a weighted average grant-date fair value of $5.01 per share. For the three and nine months ended September 30, 2022, the Company recorded $3,081 of expense related to these stock awards. ​ Stock Options ​ The Company recorded $1,025 and $1,586 of stock-based compensation expense related to employee and non-employee director stock options for the three months ended September 30, 2022 and 2021, respectively. The Company recorded $3,121 and $5,502 of stock-based compensation expense related to employee and non-employee stock options for the nine months ended September 30, 2022 and 2021, respectively. The Company records forfeitures as they occur. ​ No grants for employee and non-employee stock options were made during the nine months ended September 30, 2022. The table below sets forth the weighted average assumptions for employee grants during the nine months ended September 30, 2021: ​ ​ ​ ​ ​ ​ ​ Nine Months Ended ​ Valuation assumptions: September 30, 2021 ​ Expected volatility ​ 58.57 % Expected term (years) ​ 5.48 ​ Risk-free interest rate ​ 0.50 % Dividend yield ​ — ​ ​ The weighted average grant date fair value of employee options granted during the nine months ended September 30, 2021 was $28.26 per share. ​ The following table summarizes stock option activity under the 2016 Plan for the nine months ended September 30, 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ Weighted ​ average ​ ​ ​ ​ ​ ​ ​ average ​ remaining ​ Aggregate ​ ​ Number ​ exercise ​ contractual ​ intrinsic ​ of shares price term value Outstanding at December 31, 2021 ​ 1,604,226 ​ $ 29.90 ​ ​ ​ ​ Exercised ​ (12,830) ​ ​ 4.96 ​ ​ ​ ​ ​ Forfeited ​ (188,465) ​ ​ 44.18 ​ ​ ​ ​ ​ Outstanding at September 30, 2022 ​ 1,402,931 ​ $ 28.21 ​ 3.8 ​ $ 260 Options vested and expected to vest at September 30, 2022 ​ 1,402,931 ​ $ 28.21 ​ 3.8 ​ $ 260 Exercisable at September 30, 2022 ​ 1,370,302 ​ $ 27.57 ​ 3.8 ​ $ 260 ​ The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the Company’s closing stock price or estimated fair value on the last trading day of the fiscal quarter for those stock options that had exercise prices lower than the fair value of the Company's common stock. This amount changes based on the fair market value of the Company’s stock. The total intrinsic value of options exercised during the nine months ended September, 2022 and 2021 was $109 and $11,113, respectively. ​ As of September 30, 2022, there was $867 of total unrecognized compensation cost related to nonvested stock options granted under the 2016 Plan, which is expected to be recognized over a weighted average period of 0.4 years. ​ Cash received from option exercises for the nine months ended September 30, 2022 and 2021 was $64 and $3,683, respectively. ​ The Company recorded total stock-based compensation expense for the three and nine months ended September 30, 2022 and 2021 in the following expense categories of its consolidated statements of operations: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ September 30, ​ September 30, ​ 2022 2021 2022 2021 Cost of revenue - product ​ $ 331 ​ $ 256 ​ $ 778 ​ $ 852 Cost of revenue - service ​ ​ 793 ​ ​ 883 ​ ​ 2,264 ​ ​ 2,631 Research and development ​ ​ 1,741 ​ ​ 1,261 ​ ​ 4,021 ​ ​ 4,533 Sales and marketing ​ ​ 285 ​ ​ 209 ​ ​ 593 ​ ​ 1,251 General and administrative ​ ​ 12,228 ​ ​ 4,292 ​ ​ 20,517 ​ ​ 14,833 Discontinued operations ​ ​ 1,858 ​ ​ 1,110 ​ ​ 4,364 ​ ​ 4,862 Total stock-based compensation expense ​ $ 17,236 ​ $ 8,011 ​ $ 32,537 ​ $ 28,962 ​ ​ Employee Stock Purchase Plan In February 2021, the Board, subject to stockholder approval, adopted the Tabula Rasa HealthCare, Inc. Employee Stock Purchase Plan (the “ESPP”), which allows eligible employees to purchase common shares of Company stock through payroll deductions at a 15% discount off the lower of (i) the fair market value per share of common stock on the start date of the applicable offering period or (ii) the fair market value per share of common stock on the purchase date. The ESPP was approved by the Company’s stockholders at the 2021 annual meeting of stockholders in June 2021. The number of shares of common stock reserved for issuance under the ESPP will initially be 480,097 shares, subject to adjustment as provided in the ESPP, all of which remained available as of September 30, 2022.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2022
Fair Value Measurements
Fair Value Measurements	14. Fair Value Measurements ​ The Company’s financial instruments consist of accounts receivable, client claims receivables, contract assets, contingent consideration receivable, accounts payable, client claims payable, contract liabilities, accrued expenses, vendor financing arrangements, and long-term debt, which includes the Company’s convertible senior subordinated notes. The carrying values of accounts receivable, client claims receivables, contract assets, accounts payable, client claims payable, contract liabilities, and accrued expenses are representative of their fair values due to the relatively short-term nature of those instruments. Vendor financing arrangements are recorded at net carrying value, which approximates fair value. See below for additional information on the Company’s convertible senior subordinated notes. ​ The Company had classified assets measured at fair value on a recurring basis at September 30, 2022 as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurement ​ ​ at Reporting Date Using ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance as of ​ Level 1 Level 2 Level 3 September 30, 2022 Assets ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Contingent consideration receivable - long-term ​ $ — ​ $ — ​ $ 7,000 ​ $ 7,000 ​ In connection with the sale of the PrescribeWellness Business on August 1, 2022, additional consideration may be payable to the Company based on the achievement of certain customer and revenue metrics, as defined in the purchase agreement, for the periods ending December 31, 2023 and 2024. See Note 3 for additional information regarding the sale of the PrescribeWellness Business. ​ The contingent consideration is measured at fair value on a recurring basis and may include the use of significant unobservable inputs, hence these instruments represent Level 3 measurements within the fair value hierarchy. All changes in contingent consideration subsequent to the initial sale-date measurement are recorded in net income or loss. ​ The fair value of the contingent consideration receivable was determined using an income-approach based on projections for the achievement of the performance metrics. Changes in the projected customer and revenue metrics or discount rate may result in higher or lower fair value measurements. ​ The following table presents the financial instruments that are not carried at fair value but require fair value disclosure as of September 30, 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Face Value Carrying Value Fair Value 1.75% Convertible Senior Subordinated Notes due 2026 ​ $ 325,000 ​ $ 320,297 ​ $ 258,131 ​ The fair value of the 2026 Notes at each balance sheet date is determined based on recent quoted market prices for these notes which is a Level 2 measurement. As discussed in Note 11, the 2026 Notes are carried at their aggregate face value of $325,000, less any unamortized debt issuance costs.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies
Commitments and Contingencies	15. Commitments and Contingencies ​ (a) Employment Agreements ​ The Company has change-in-control and severance agreements with each of the Company’s named executive officers and other key members of management that provide for, among other things, salary, performance bonuses or other incentive compensation, payments in the event of termination of the executives upon the occurrence of a change in control, and restrictive covenants pursuant to which the employees have agreed to refrain from competing with the Company or soliciting the Company’s employees or clients for a period following the employee’s termination of employment. ​ (b) Legal Proceedings ​ The Company is not currently involved in any significant claims or legal actions that, in the opinion of management, are expected to have a material adverse impact on the Company. ​ (c) Vendor Purchase Agreements ​ On March 29, 2019, the Company entered into an Affiliated Pharmacy Agreement and Pharmaceutical Program Supply Agreement (the “Prior Thrifty Drug Agreements”) with Thrifty Drug Stores, Inc. (“Thrifty Drug”). On July 1, 2020, the Company entered into a new Affiliated Pharmacy Agreement and Pharmaceutical Program Supply Agreement with Thrifty Drug (the “Thrifty Drug Agreements”) to replace the Prior Thrifty Drug Agreements, which, among other things, extended the Company’s agreement with Thrifty Drug through September 30, 2023. Pursuant to the terms of the Thrifty Drug Agreements, the Company has agreed to purchase not less than 98% of the Company’s total prescription product requirements from Thrifty Drug. The Company commenced purchasing prescription products under the Prior Thrifty Drug Agreements in May 2019 and has continued to do so under the Thrifty Drug Agreements beginning in July 2020. Both the Prior Thrifty Drug Agreements and the Thrifty Drug Agreements authorize Thrifty Drug to hold a security interest in all of the products purchased by the Company under the respective agreements. ​ As of September 30, 2022 and December 31, 2021 the Company had $1,993 and $1,854, respectively, due to Thrifty Drug as a result of prescription drug purchases. ​ In December 2019, the Company entered into an updated agreement with its data aggregation partner related to the Company’s pharmacy cost management services. The agreement is effective January 1, 2020 with a three-year term expiring December 31, 2022 and commits the Company to a monthly minimum purchase obligation of $30. ​ In June 2021 and October 2021, the Company entered into agreements with a provider for cloud hosting and support services. The June 2021 agreement was effective June 3, 2021 and expires on April 28, 2024. Pursuant to the June 2021 agreement, the Company is committed to a minimum purchase obligation of $1,272 over the term of the agreement. The October 2021 agreement was effective October 1, 2021 and expires on September 30, 2024. Pursuant to the October 2021 agreement, the Company is committed to a minimum purchase obligation of $7,050 over the term of the agreement. Commitments under the October 2021 agreement are inclusive of commitments under the June 2021 agreement. As of September 30, 2022, the Company had a remaining commitment of $4,700 under the October 2021 agreement, of which $691 pertained to the June 2021 agreement. ​ In August 2021, the Company entered into an agreement with a third party to provide enterprise support and information technology services. The agreement is effective November 1, 2021 and expires on October 31, 2026 and commits the Company to a minimum purchase obligation of $8,960 through October 31, 2024. As of September 30, 2022, the Company had a remaining commitment of $6,222. ​ In November 2021, the Company entered into an agreement with a provider for cloud hosting services. The agreement is effective November 25, 2021 and expires on November 25, 2022 and commits the Company to a minimum purchase obligation of $1,598 over the contract term. As of September 30, 2022, the Company had a remaining commitment of $243. ​ ​

Segment Reporting

Segment Reporting	9 Months Ended
	Sep. 30, 2022
Segment Reporting
Segment Reporting	16. Segment Reporting ​ The Company operates its business through two segments. As discussed in Note 3 above, the divestiture of the PrescribeWellness Business and the planned SinfoníaRx businesses, which collectively comprised the majority of the Company’s MedWise HealthCare segment, ​ The Company's chief operating decision maker (“CODM”), the Chief Executive Officer, allocates resources and assesses performance based upon financial information at the reportable segment level. Substantially all revenues are generated and substantially all tangible assets are held in the U.S. ​ CareVention HealthCare primarily provides services to PACE organizations that include medication fulfillment pharmacy services and PACE solutions, such as medication safety services, PBM solutions, and health plan management services . ​ MedWise HealthCare primarily generates revenues from medication safety services and software subscription solutions, ​ Shared services primarily consist of unallocated corporate sales and marketing expenses and general and administrative expenses associated with the management and administration of the Company’s business objectives. ​ The CODM uses revenue in accordance with GAAP and Adjusted EBITDA as the relevant segment performance measures to evaluate the performance of the segments and allocate resources. ​ Adjusted EBITDA is a segment performance financial measure that offers a useful view of the overall operation of the Company’s businesses and may be different from similarly titled segment performance financial measures used by other companies. ​ Adjusted EBITDA consists of net loss plus certain other expenses, which include interest expense, provision for income taxes, depreciation and amortization, impairment charges, business optimization expenses, severance costs, executive transition costs, cooperation agreement costs, divestiture-related expense, acquisition-related expense, stock-based compensation expense, loss on disposal of business, and settlement costs. The Company considers business optimization expenses to include contract termination payments, severance, retention payments, and other employee and non-recurring vendor costs incurred related to its business optimization initiatives during 2022. The Company considers severance costs to include severance payments related to the realignment of its resources. The Company considers executive transition costs to include nonrecurring costs related to the hiring and onboarding of new named executive officers and separation costs related to former named executive officers. The Company considers cooperation agreement costs to include legal, professional services, and other non-recurring costs related to the Company’s cooperation agreement with Indaba Capital Management. The Company considers divestiture-related expense to include nonrecurring direct transaction costs. The Company considers acquisition-related expense to include nonrecurring direct transaction and integration costs. The Company considers loss on disposal of business to include nonrecurring loss resulting from the sale of PrescribeWellness Business. The Company considers settlement costs to include amounts payable by the Company or reductions to amounts owed to the Company as a result of a contractual settlement. ​ Management considers revenue and Adjusted EBITDA to be the appropriate metric to evaluate and compare the ongoing operating performance of the Company’s segments on a consistent basis across reporting periods as it eliminates the effect of items which are not indicative of each segment’s core operating performance. ​ The following tables present the Company’s segment information: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ CareVention HealthCare ​ Shared Services and Other ​ Consolidated Revenue: ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ Product revenue ​ $ 59,780 ​ $ — ​ $ 59,780 Service revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ PACE solutions ​ ​ 16,416 ​ ​ — ​ ​ 16,416 Medication safety services ​ ​ — ​ ​ 843 ​ ​ 843 Software subscription and services ​ ​ — ​ ​ 62 ​ ​ 62 Total service revenue ​ ​ 16,416 ​ ​ 905 ​ ​ 17,321 Total revenue ​ $ 76,196 ​ $ 905 ​ $ 77,101 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ Product revenue ​ $ 50,321 ​ $ — ​ $ 50,321 Service revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ PACE solutions ​ ​ 14,707 ​ ​ — ​ ​ 14,707 Medication safety services ​ ​ — ​ ​ 2,820 ​ ​ 2,820 Software subscription and services ​ ​ — ​ ​ 62 ​ ​ 62 Total service revenue ​ ​ 14,707 ​ ​ 2,882 ​ ​ 17,589 Total revenue ​ $ 65,028 ​ $ 2,882 ​ $ 67,910 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ Product revenue ​ $ 166,645 ​ $ — ​ $ 166,645 Service revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ PACE solutions ​ ​ 47,604 ​ ​ — ​ ​ 47,604 Medication safety services ​ ​ — ​ ​ 2,336 ​ ​ 2,336 Software subscription and services ​ ​ — ​ ​ 223 ​ ​ 223 Total service revenue ​ ​ 47,604 ​ ​ 2,559 ​ ​ 50,163 Total revenue ​ $ 214,249 ​ $ 2,559 ​ $ 216,808 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ Product revenue ​ $ 139,021 ​ $ — ​ $ 139,021 Service revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ PACE solutions ​ ​ 42,973 ​ ​ — ​ ​ 42,973 Medication safety services ​ ​ — ​ ​ 8,817 ​ ​ 8,817 Software subscription and services ​ ​ — ​ ​ 174 ​ ​ 174 Total service revenue ​ ​ 42,973 ​ ​ 8,991 ​ ​ 51,964 Total revenue ​ $ 181,994 ​ $ 8,991 ​ $ 190,985 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ CareVention HealthCare ​ Shared Services and Other ​ Consolidated Adjusted EBITDA (loss) from Continuing Operations: ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjusted EBITDA (loss) ​ $ 14,051 ​ $ (11,998) ​ $ 2,053 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjusted EBITDA (loss) ​ $ 14,014 ​ $ (10,875) ​ $ 3,139 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjusted EBITDA (loss) ​ $ 39,531 ​ $ (34,339) ​ $ 5,192 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjusted EBITDA (loss) ​ $ 40,983 ​ $ (32,998) ​ $ 7,985 ​ The following table presents the Company’s reconciliation net loss as presented in the consolidated statements of operations to the segments’ total Adjusted EBITDA: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ 2022 2021 2022 2021 Reconciliation of Net Loss to Adjusted EBITDA from Continuing Operations ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss ​ $ (40,065) ​ $ (17,111) ​ $ (117,868) ​ $ (57,684) Add: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Interest expense, net ​ ​ 2,717 ​ ​ 2,230 ​ ​ 7,430 ​ ​ 6,959 Income tax (benefit) expense ​ ​ (7) ​ ​ 82 ​ ​ 368 ​ ​ 284 Depreciation and amortization ​ ​ 5,723 ​ ​ 5,328 ​ ​ 16,954 ​ ​ 15,109 Impairment charges ​ ​ — ​ ​ — ​ ​ 4,062 ​ ​ — Business optimization expenses ​ ​ — ​ ​ — ​ ​ 787 ​ ​ — Severance costs ​ ​ 122 ​ ​ 354 ​ ​ 697 ​ ​ 516 Executive transition ​ ​ 1,821 ​ ​ — ​ ​ 1,971 ​ ​ — Cooperation agreement costs ​ ​ 1,122 ​ ​ — ​ ​ 1,122 ​ ​ — Divestiture-related expense ​ ​ 1,057 ​ ​ — ​ ​ 2,591 ​ ​ — Acquisition-related expense ​ ​ — ​ ​ — ​ ​ — ​ ​ 217 Stock-based compensation expense ​ ​ 15,378 ​ ​ 6,901 ​ ​ 28,173 ​ ​ 24,100 Loss from discontinued operations ​ ​ 14,185 ​ ​ 5,355 ​ ​ 58,905 ​ ​ 18,484 Adjusted EBITDA from continuing operations ​ $ 2,053 ​ $ 3,139 ​ $ 5,192 ​ $ 7,985 Adjusted EBITDA (loss) from discontinued operations ​ ​ (3,593) ​ ​ 2,578 ​ ​ (1,036) ​ ​ 7,294 Total Adjusted EBITDA (loss) ​ $ (1,540) ​ $ 5,717 ​ $ 4,156 ​ $ 15,279 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ 2022 2021 2022 2021 Reconciliation of Net Loss from Discontinued Operations, net of tax to Adjusted EBITDA (Loss) from Discontinued Operations ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss from discontinued operations, net of tax ​ $ (14,185) ​ $ (5,355) ​ $ (58,905) ​ $ (18,484) Add: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Income tax (benefit) expense ​ ​ (94) ​ ​ 52 ​ ​ (662) ​ ​ 182 Depreciation and amortization ​ ​ — ​ ​ 6,771 ​ ​ 7,331 ​ ​ 20,234 Impairment charges ​ ​ 5,845 ​ ​ — ​ ​ 42,293 ​ ​ — Loss on disposal of business ​ ​ 2,879 ​ ​ — ​ ​ 2,879 ​ ​ — Settlement ​ ​ — ​ ​ — ​ ​ 1,448 ​ ​ 500 Divestiture-related expense ​ ​ 104 ​ ​ — ​ ​ 216 ​ ​ — Stock-based compensation expense ​ ​ 1,858 ​ ​ 1,110 ​ ​ 4,364 ​ ​ 4,862 Adjusted EBITDA (loss) from discontinued operations ​ $ (3,593) ​ $ 2,578 ​ $ (1,036) ​ $ 7,294 ​ Asset information by segment is not a key measure of performance used by the CODM. Accordingly, the Company has not disclosed asset information by segment.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2022
Related Party Transactions
Related Party Transactions	17. Related Party Transactions ​ The Company’s CareVention HealthCare segment provides medication fulfillment pharmacy services and certain PACE solutions services to a client whose Chief Executive Officer is a member of the Board. For the three months ended September 30, 2022 and 2021, $1,894 and $1,679 , respectively, of revenue related to this client was included in the Company’s consolidated statements of operations. For the nine months ended September 30, 2022 and 2021, $5,541 and $4,834 , respectively, of revenue related to this client was included in the Company’s consolidated statements of operations. As of September 30, 2022 and December 31, 2021, $225 and $67 , respectively, was included in accounts receivable, net, on the Company’s consolidated balance sheets. ​ During the second quarter of 2022, a holder of the Company’s convertible senior subordinated notes became a significant stockholder. The stockholder held approximately $88,429 of the Company’s convertible senior subordinated notes, net of discount, which is presented on the Company’s consolidated balance sheet as of September 30, 2022. See Note 11 for more information on the Company’s convertible senior subordinated notes. ​ On September 13, 2022, the Company entered into a cooperation agreement (the “Cooperation Agreement”) with a significant stockholder of the Company, pursuant to which, among other matters, the Company agreed to effect certain changes to its management team and the composition of the Board of Directors and implement certain corporate governance changes. In connection with the Cooperation Agreement, the Company agreed to reimburse the stockholder $464 of fees incurred, which are included within the accrued expenses and other liabilities on the Company’s consolidated balance sheet as of September 30, 2022. ​ On September 13, 2022, in connection with the entry into separation agreements with two retired named executive officers, the Company incurred $9,927 of separation costs, which included stock-based compensation related to the accelerated vesting of unvested shares of restricted stock, severance payments and benefits, relevant payroll taxes, and outplacement services. These costs are included within general and administrative expenses on the Company’s consolidated statement of operations, of which $1,616 are included within accrued expenses and other liabilities on the Company’s consolidated balance sheet as of September 30, 2022. ​ On September 13, 2022, the Company entered into

Rights Plan

Rights Plan	9 Months Ended
	Sep. 30, 2022
Warrants and Rights Note Disclosure [Abstract]
Rights Plan	18. Rights Plan ​ On July 25, 2022, the Board approved and adopted a Rights Agreement (the “Rights Agreement”), by and between the Company and American Stock Transfer & Trust Company, LLC, as Rights Agent. Pursuant to the Rights Agreement, the Board declared a dividend of one preferred share purchase right (each, a “Right”) for each outstanding share of common stock. The Rights are distributable to stockholders of record as of the close of business on August 5, 2022 and are not exercisable initially. If the Rights become exercisable, each Right entitles the registered holder to purchase from the Company one ​ ​

Basis of Presentation, Summar_2

Basis of Presentation, Summary of Significant Accounting Policies, and Recent Accounting Pronouncements (Policies)	9 Months Ended
	Sep. 30, 2022
Basis of Presentation, Summary of Significant Accounting Policies, and Recent Accounting Pronouncements
Basis of Presentation	(a) Basis of Presentation ​ The accompanying unaudited consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. The unaudited interim consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring accruals and adjustments) necessary to present fairly the Company’s interim consolidated financial position for the periods indicated. The interim results for the three and nine months ended September 30, 2022 are not necessarily indicative of results to be expected for the year ending December 31, 2022, any other interim periods, or any future year or period. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K filed with the SEC on February 25, 2022 (the “2021 Form 10-K”). ​ Except as described below, there have been no material changes to the Company’s significant accounting policies described in the 2021 Form 10-K that have a material impact on the Company’s accompanying unaudited consolidated financial statements and related notes.
Assets and Liabilities Held for Sale and Discontinued Operations	(b) Assets and Liabilities Held for Sale and Discontinued Operations ​ A long-lived asset (or disposal group) is classified as held for sale if its carrying amount will be recovered principally through a sale transaction rather than through continuing use and a sale is considered highly probable within a year. A long-lived asset (or disposal group) classified as held for sale is initially measured at the lower of its carrying amount or fair value less costs to sell. An impairment loss is recognized for any initial or subsequent write-down of the long-lived asset (or disposal group) to fair value less costs to sell. A gain or loss not previously recognized by the date of the sale of the long-lived asset (or disposal group) is recognized at the date of derecognition. ​ Long-lived assets (including those that are part of a disposal group) are not depreciated or amortized while they are classified as held for sale. Long-lived assets classified as held for sale and the assets of a disposal group classified as held for sale are presented separately from the other assets in the balance sheet. The liabilities of a disposal group classified as held for sale are presented separately from other liabilities in the balance sheet. ​ Unless otherwise noted, amounts and disclosures throughout the notes to the unaudited consolidated financial statements relate to the Company’s continuing operations. ​ Additional details surrounding the Company’s assets and liabilities held for sale and discontinued operations are included in Note 3.
Cloud Computing Arrangements	(c) Cloud Computing Arrangements ​ Costs to implement cloud computing arrangements that are hosted by third-party vendors are capitalized when incurred during the application development phase. Capitalized implementation costs are amortized on a straight-line basis over the reasonably certain term of the hosting arrangement, beginning when the service is ready for its intended use. As of September 30, 2022 and December 31, 2021, capitalized implementation costs of $882 and $747, respectively, were included in prepaid expenses, and $1,276 and $0, respectively, were included in other assets on the Company’s consolidated balance sheets. Accumulated amortization for these arrangements was $554 and $398 as of September 30, 2022 and December 31, 2021, respectively. Amortization expense for the three months ended September 30, 2022 and 2021, was $51 and $53, respectively. Amortization expense for the nine months ended September 30, 2022 and 2021, was $156 and $155, respectively.
Vendor Financing Arrangements	(d) Vendor Financing Arrangements ​ On February 24, 2022, the Company expanded its existing relationship with a third-party service provider for business process outsourcing and technology services for its third-party administration services and electronic health records solutions. As a result, the third-party provider hired approximately 180 employees from the Company, hired to fill existing open positions and will augment with additional resources to meet client demand. The agreement term is seven years and includes total estimated fees of $115,300. ​ The arrangement includes extended payment terms for cloud computing implementation costs, internally developed software support, and business process support. In order to determine the present value of the commitment, the Company used an imputed interest rate of 9.5%, which was reflective of its estimated uncollateralized borrowing rate at signing. As of September 30, 2022, the outstanding principal balance of the financing arrangement was $3,772 with an unamortized discount of $876, and was included in accrued expenses and other liabilities and other long-term liabilities on the Company’s consolidated balance sheet. Imputed interest expense from the arrangement was $53 and $89 for the three and nine months ended September 30, 2022, respectively.
Concentration of Credit Risk	(e) Concentrations of Credit Risk ​ The Company is subject to concentrations of credit risk related to cash, restricted cash, accounts receivable, and client claims receivable. While the Company maintains its cash and restricted cash with financial institutions with high credit ratings, it often maintains these deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any realized losses on cash or restricted cash to date. ​ The Company’s medication fulfillment services clients are sponsors of the federal Medicare Part D plan (prescription drug coverage plan) and, therefore, subject to the payment regulations established by the Centers for Medicare & Medicaid Services (“CMS”). Under CMS guidelines, Medicare Part D sponsors are required to remit payment for claims within 14 ​ The Company’s clients also include health plans and other healthcare providers. Credit associated with these accounts is extended based upon management’s evaluation of creditworthiness and is monitored on an on-going basis. ​ As of September 30, 2022 and December 31, 2021, no client represented more than 10% of net accounts receivable. ​ As of September 30, 2022 one client represented 21% of client claims receivable. As of December 31, 2021, two clients represented 13% and 11%, respectively, of client claims receivable. ​ One client accounted for 15% and 13% of total revenue for the three months ended September 30, 2022 and 2021, respectively, and 16% and 14% of total revenue for the nine months ended September 30, 2022 and 2021, respectively. ​
Recent Accounting Pronouncement	(f) Recent Accounting Pronouncement In October 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2021-08, Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”). ASU 2021-08 requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities from acquired contracts using the revenue recognition guidance under ASC Topic 606 (Revenue from Contracts with Customers) in order to align the recognition of a contract liability with the definition of performance obligation. This approach differs from the current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value. ASU 2021-08 is effective for financial statements issued for fiscal years beginning after December 15, 2022; early adoption is permitted. The Company plans to adopt ASU 2021-08 on January 1, 2023 and does not expect it to have a significant impact on the consolidated financial statements.

Discontinued Operations (Tables

Discontinued Operations (Tables)	9 Months Ended
	Sep. 30, 2022
PrescribeWellness business | Discontinued Operations, Disposed of by Sale
Discontinued Operations
Schedules of discontinued operations	The following table summarizes the net assets sold as finally reported on the sale date of August 1, 2022 and as of December 31, 2021, classified as discontinued operations on the consolidated balance sheets as of December 31, 2021: ​ ​ ​ ​ ​ ​ ​ August 1, ​ December 31, ​ 2022 2021 Accounts receivable, net $ 5,020 ​ ​ 8,002 Prepaid expenses and other assets ​ 1,751 ​ ​ 1,038 Property and equipment, net ​ 371 ​ ​ — Operating lease right-of-use assets ​ 1,252 ​ ​ — Software development costs, net ​ 14,536 ​ ​ — Goodwill ​ 35,314 ​ ​ — Intangible assets, net ​ 81,504 ​ ​ — Impairment of carrying value ​ (8,500) ​ ​ — Total current assets of discontinued operations $ 131,248 ​ $ 9,040 ​ ​ ​ ​ ​ ​ Property and equipment, net $ — ​ $ 412 Operating lease right-of-use assets ​ — ​ ​ 1,434 Software development costs, net ​ — ​ ​ 11,474 Goodwill ​ — ​ ​ 47,459 Intangible assets, net ​ — ​ ​ 84,617 Other assets ​ — ​ ​ 64 Total noncurrent assets of discontinued operations $ — ​ $ 145,460 ​ ​ ​ ​ ​ ​ Operating lease liabilities $ 1,086 ​ $ 620 Accounts payable ​ 491 ​ ​ 913 Accrued expenses and other liabilities ​ 2,754 ​ ​ 3,529 Total current liabilities of discontinued operations $ 4,331 ​ $ 5,062 ​ ​ ​ ​ ​ ​ Noncurrent operating lease liabilities $ — ​ $ 830 Other long-term liabilities ​ — ​ ​ 135 Total noncurrent liabilities of discontinued operations $ — ​ $ 965 ​ The following table summarizes the results of operations of the PrescribeWellness Business, which are included in loss from discontinued operations, net of tax in the consolidated statements of operations for the three and nine months ended September 30, 2022 and 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ September 30, ​ September 30, ​ 2022 2021 ​ 2022 2021 Revenue $ 2,537 ​ $ 10,533 ​ $ 19,306 ​ $ 27,629 Cost of revenue, exclusive of depreciation and amortization ​ 1,229 ​ ​ 3,426 ​ ​ 7,747 ​ ​ 9,883 Operating expenses ​ 2,336 ​ ​ 8,373 ​ ​ 14,930 ​ ​ 24,427 Impairment charges ​ — ​ ​ — ​ ​ 20,645 ​ ​ — Loss on disposal of business ​ 2,879 ​ ​ — ​ ​ 2,879 ​ ​ — Loss from discontinued operations before income taxes ​ (3,907) ​ ​ (1,266) ​ ​ (26,895) ​ ​ (6,681) Income tax (benefit) expense ​ (11) ​ ​ 12 ​ ​ (299) ​ ​ 66 Net loss from discontinued operations, net of tax $ (3,896) ​ $ (1,278) ​ $ (26,596) ​ $ (6,747) ​ The following table summarizes the significant operating non-cash items and investing activities of PrescribeWellness Business: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended ​ ​ September 30, ​ 2022 2021 Depreciation and amortization ​ $ 4,551 ​ $ 12,059 Impairment charges ​ ​ 20,645 ​ ​ — Stock-based compensation ​ ​ 1,697 ​ ​ 2,352 Loss on disposal of business ​ ​ 2,879 ​ ​ — Purchases of property and equipment ​ ​ (22) ​ ​ (305) Software development costs ​ ​ (4,443) ​ ​ (9,783)
DoseMe and SinfonaRx businesses | Discontinued Operations, Held-for-sale
Discontinued Operations
Schedules of discontinued operations	The following table s ummarizes the results of operations of the businesses, which are included in loss from discontinued operations, net of tax in the consolidated statements of operations for the three and nine months ended September 30, 2022 and 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ September 30, ​ September 30, ​ 2022 2021 ​ 2022 2021 Revenue $ 6,407 ​ $ 8,143 ​ $ 23,094 ​ $ 26,961 Cost of revenue, exclusive of depreciation and amortization ​ 7,055 ​ ​ 6,521 ​ ​ 20,479 ​ ​ 19,755 Operating expenses ​ 3,879 ​ ​ 5,659 ​ ​ 13,639 ​ ​ 18,827 Impairment charges ​ 5,845 ​ ​ — ​ ​ 21,648 ​ ​ — Loss from discontinued operations before income taxes ​ (10,372) ​ ​ (4,037) ​ ​ (32,672) ​ ​ (11,621) Income tax (benefit) expense ​ (83) ​ ​ 40 ​ ​ (363) ​ ​ 116 Net loss from discontinued operations, net of tax $ (10,289) ​ $ (4,077) ​ $ (32,309) ​ $ (11,737) ​ The following table summarizes the DoseMe and SinfoníaRx businesses’ current and noncurrent assets and liabilities classified as discontinued operations on the consolidated balance sheets as of September 30, 2022 and December 31, 2021: ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ 2022 2021 Cash $ 69 ​ $ 273 Accounts receivable, net ​ 4,964 ​ ​ 4,644 Prepaid expenses and other assets ​ 796 ​ ​ 554 Property and equipment, net ​ 1,349 ​ ​ — Operating lease right-of-use assets ​ 3,732 ​ ​ — Software development costs, net ​ 6,910 ​ ​ — Goodwill ​ 1,927 ​ ​ — Intangible assets, net ​ 22,635 ​ ​ — Impairment of carrying value ​ (15,521) ​ ​ — Total current assets of discontinued operations $ 26,861 ​ $ 5,471 ​ ​ ​ ​ ​ ​ Property and equipment, net $ — ​ $ 1,485 Operating lease right-of-use assets ​ — ​ ​ 3,296 Software development costs, net ​ — ​ ​ 4,466 Goodwill ​ — ​ ​ 8,053 Intangible assets, net ​ — ​ ​ 24,675 Other assets ​ — ​ ​ 123 Total noncurrent assets of discontinued operations $ — ​ $ 42,098 ​ ​ ​ ​ ​ ​ Operating lease liabilities $ 3,458 ​ $ 793 Accounts payable ​ 3,077 ​ ​ 3,395 Accrued expenses and other liabilities ​ 4,597 ​ ​ 3,130 Total current liabilities of discontinued operations $ 11,132 ​ $ 7,318 ​ ​ ​ ​ ​ ​ Noncurrent operating lease liabilities ​ — ​ $ 2,608 Other long-term liabilities ​ — ​ ​ — Total noncurrent liabilities of discontinued operations $ — ​ $ 2,608 The following table summarizes the DoseMe and SinfoníaRx businesses’ significant operating non-cash items and investing activities of discontinued operations: ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended ​ ​ September 30, ​ 2022 2021 Depreciation and amortization ​ $ 2,780 ​ $ 8,175 Impairment charges ​ ​ 21,648 ​ ​ — Stock-based compensation ​ ​ 2,667 ​ ​ 2,510 Purchases of property and equipment ​ ​ (50) ​ ​ (1,323) Software development costs ​ ​ (2,998) ​ ​ (6,155)

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Sep. 30, 2022
Revenue.
Schedule of disaggregation of revenue	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ September 30, ​ September 30, ​ ​ ​ 2022 ​ ​ 2021 ​ ​ 2022 ​ ​ 2021 CareVention HealthCare: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ PACE product revenue ​ $ 59,780 ​ $ 50,321 ​ $ 166,645 ​ $ 139,021 PACE solutions ​ ​ 16,416 ​ ​ 14,707 ​ ​ 47,604 ​ ​ 42,973 ​ ​ $ 76,196 ​ $ 65,028 ​ $ 214,249 ​ $ 181,994 MedWise HealthCare: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Medication safety services ​ $ 843 ​ $ 2,820 ​ $ 2,336 ​ $ 8,817 Software subscription and services ​ ​ 62 ​ ​ 62 ​ ​ 223 ​ ​ 174 ​ ​ $ 905 ​ $ 2,882 ​ $ 2,559 ​ $ 8,991 Total revenue ​ $ 77,101 ​ $ 67,910 ​ $ 216,808 ​ $ 190,985
Schedule of contract assets and contract liabilities from contracts with customers	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ ​ 2022 2021 Contract assets ​ $ 15,072 ​ $ 12,695 Contract liabilities ​ ​ 4,110 ​ ​ 2,191
Schedule of significant changes in the contract assets and the contract liabilities balances	​ ​ ​ ​ ​ ​ ​ September 30, ​ ​ 2022 Contract assets: ​ ​ ​ Contract assets, beginning of period ​ $ 12,695 Decreases due to cash received ​ ​ (12,466) Changes to the contract assets at the beginning of the period as a result of changes in estimates ​ ​ 451 Changes during the year, net of reclassifications to receivables ​ ​ 14,392 Contract assets, end of period ​ $ 15,072 ​ ​ ​ ​ Contract liabilities: ​ ​ ​ Contract liabilities, beginning of period ​ $ 2,191 Revenue recognized that was included in the contract liabilities balance at the beginning of the period ​ ​ (1,903) Increases due to cash received, excluding amounts recognized as revenue during the year ​ ​ 3,822 Contract liabilities, end of period ​ $ 4,110

Net Loss per Share (Tables)

Net Loss per Share (Tables)	9 Months Ended
	Sep. 30, 2022
Net Loss per Share
Schedule of calculation of basic and diluted net loss per share	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ September 30, ​ September 30, ​ 2022 2021 2022 2021 Numerator (basic and diluted): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss from continuing operations ​ $ (25,880) ​ $ (11,756) ​ $ (58,963) ​ $ (39,200) Net loss from discontinued operations ​ ​ (14,185) ​ ​ (5,355) ​ ​ (58,905) ​ ​ (18,484) Net loss ​ $ (40,065) ​ $ (17,111) ​ $ (117,868) ​ $ (57,684) Denominator (basic and diluted): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average shares of common stock outstanding, basic and diluted ​ ​ 24,350,182 ​ ​ 23,407,391 ​ ​ 24,075,666 ​ ​ 23,230,138 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss per share from continuing operations, basic and diluted ​ $ (1.07) ​ $ (0.50) ​ $ (2.45) ​ $ (1.68) Net loss per share from discontinued operations, basic and diluted ​ ​ (0.58) ​ ​ (0.23) ​ ​ (2.45) ​ ​ (0.80) Total net loss per share, basic and diluted ​ $ (1.65) ​ $ (0.73) ​ $ (4.90) ​ $ (2.48)
Schedule of shares excluded from the calculation of diluted net loss per share attributable to common stockholders	​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ 2022 2021 Stock options to purchase common stock ​ 1,402,931 ​ 1,671,680 Unvested restricted stock and restricted stock units ​ 2,217,033 ​ 1,624,523 Common stock warrants ​ 4,646,393 ​ 4,646,393 Conversion of convertible senior subordinated notes ​ 4,646,393 ​ 4,646,393 ​ ​ 12,912,750 ​ 12,588,989

Other Current Assets (Tables)

Other Current Assets (Tables)	9 Months Ended
	Sep. 30, 2022
Other Current Assets
Schedule of Other Current Assets	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2022 December 31, 2021 Contract assets ​ $ 15,072 ​ $ 12,695 Non-trade receivables ​ ​ 1,235 ​ ​ 3,289 Divestiture related consideration receivables ​ ​ 1,477 ​ ​ — Other ​ ​ 2,655 ​ ​ 2,049 Total other current assets ​ $ 20,439 ​ $ 18,033

Software Development Costs (Tab

Software Development Costs (Tables)	9 Months Ended
	Sep. 30, 2022
Software Development Costs
Schedule of capitalized software costs	​ ​ ​ ​ ​ ​ ​ ​ September 30, 2022 December 31, 2021 Software development costs $ 51,305 ​ $ 49,481 Less: accumulated amortization ​ (18,699) ​ ​ (20,227) Software development costs, net $ 32,606 ​ $ 29,254 ​ ​ ​ ​ ​ ​ Capitalized software development costs included above not yet subject to amortization $ 4,505 ​ $ 5,328

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets
Schedule of intangible assets	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortization Period ​ ​ ​ ​ Accumulated ​ Intangible ​ (in years) Gross Value Amortization Assets, net September 30, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Trade names ​ 2.6 ​ $ 1,340 ​ $ (982) ​ $ 358 Client relationships ​ 11.7 ​ ​ 51,264 ​ ​ (14,438) ​ ​ 36,826 Non-competition agreements ​ 5.0 ​ ​ 1,640 ​ ​ (1,221) ​ ​ 419 Developed technology ​ 6.2 ​ ​ 14,720 ​ ​ (12,076) ​ ​ 2,644 Domain name ​ 10.0 ​ ​ 59 ​ ​ (31) ​ ​ 28 Total intangible assets ​ ​ ​ $ 69,023 ​ $ (28,748) ​ $ 40,275 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortization Period ​ ​ ​ ​ Accumulated ​ Intangible ​ (in years) Gross Value Amortization Assets, net December 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Trade names ​ 2.9 ​ $ 1,340 ​ $ (853) ​ $ 487 Client relationships ​ 11.7 ​ ​ 51,264 ​ ​ (11,042) ​ ​ 40,222 Non-competition agreements ​ 5.0 ​ ​ 1,640 ​ ​ (975) ​ ​ 665 Developed technology ​ 6.2 ​ ​ 14,720 ​ ​ (10,768) ​ ​ 3,952 Domain name ​ 10.0 ​ ​ 59 ​ ​ (27) ​ ​ 32 Total intangible assets ​ ​ ​ $ 69,023 ​ $ (23,665) ​ $ 45,358
Schedule of estimated amortization expense	​ ​ ​ ​ ​ Years Ending December 31, ​ ​ 2022 (October 1 – December 31) ​ $ 1,669 2023 ​ ​ 6,162 2024 ​ ​ 4,684 2025 ​ ​ 4,466 2026 ​ ​ 4,338 2027 ​ ​ 4,271 Thereafter ​ ​ 14,685 Total estimated amortization expense ​ $ 40,275

Accrued Expenses and Other Li_2

Accrued Expenses and Other Liabilities (Tables)	9 Months Ended
	Sep. 30, 2022
Accrued Expenses and Other Liabilities
Schedule of accrued expenses and other liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2022 December 31, 2021 Employee related expenses ​ $ 8,961 ​ $ 8,595 Contract liability ​ ​ 3,864 ​ ​ 2,015 Customer deposits ​ ​ 903 ​ ​ 904 Client funds obligations* ​ ​ 7,389 ​ ​ 6,038 Contract labor ​ ​ 2,852 ​ ​ 838 Divestiture closing fees ​ ​ 3,000 ​ ​ — Interest ​ ​ 711 ​ ​ 2,281 Vendor financing arrangements ​ ​ 176 ​ ​ — Professional fees ​ ​ 2,161 ​ ​ 1,327 Consideration payable to customer ​ ​ 24,500 ​ ​ 15,971 Income and non-income taxes payable ​ ​ 95 ​ ​ 15 Other expenses ​ ​ 4,895 ​ ​ 3,013 Total accrued expenses and other liabilities ​ $ 59,507 ​ $ 40,997 ​ *This amount represents client funds held by the Company, with an offsetting amount included in restricted cash.

Line of Credit and Long-Term _2

Line of Credit and Long-Term Debt (Tables)	9 Months Ended
	Sep. 30, 2022
Lines of Credit and Long-Term Debt
Schedule of long-term debt obligations	​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2022 December 31, 2021 Convertible senior subordinated notes ​ $ 235,272 ​ $ 325,000 Convertible senior subordinated notes - related party ​ ​ 89,728 ​ ​ — Unamortized discount, including debt issuance costs, on convertible senior subordinated notes ​ ​ (4,703) ​ ​ (5,701) Total long-term debt, net ​ $ 320,297 ​ $ 319,299

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2022
Stock-Based Compensation
Summary of restricted stock award activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ average ​ ​ Number ​ grant-date ​ of shares fair value Outstanding at December 31, 2021 ​ 2,196,566 ​ $ 40.19 Granted ​ 1,935,883 ​ ​ 4.44 Vested ​ (1,224,471) ​ ​ 34.32 Forfeited ​ (676,723) ​ ​ 16.40 Outstanding at September 30, 2022 ​ 2,231,255 ​ $ 19.61
Schedule of weighted average assumptions for employee grants	​ ​ ​ ​ ​ ​ ​ Nine Months Ended ​ Valuation assumptions: September 30, 2021 ​ Expected volatility ​ 58.57 % Expected term (years) ​ 5.48 ​ Risk-free interest rate ​ 0.50 % Dividend yield ​ — ​
Summary of stock option activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ Weighted ​ average ​ ​ ​ ​ ​ ​ ​ average ​ remaining ​ Aggregate ​ ​ Number ​ exercise ​ contractual ​ intrinsic ​ of shares price term value Outstanding at December 31, 2021 ​ 1,604,226 ​ $ 29.90 ​ ​ ​ ​ Exercised ​ (12,830) ​ ​ 4.96 ​ ​ ​ ​ ​ Forfeited ​ (188,465) ​ ​ 44.18 ​ ​ ​ ​ ​ Outstanding at September 30, 2022 ​ 1,402,931 ​ $ 28.21 ​ 3.8 ​ $ 260 Options vested and expected to vest at September 30, 2022 ​ 1,402,931 ​ $ 28.21 ​ 3.8 ​ $ 260 Exercisable at September 30, 2022 ​ 1,370,302 ​ $ 27.57 ​ 3.8 ​ $ 260
Schedule of recorded stock-based compensation expense related to stock options	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ September 30, ​ September 30, ​ 2022 2021 2022 2021 Cost of revenue - product ​ $ 331 ​ $ 256 ​ $ 778 ​ $ 852 Cost of revenue - service ​ ​ 793 ​ ​ 883 ​ ​ 2,264 ​ ​ 2,631 Research and development ​ ​ 1,741 ​ ​ 1,261 ​ ​ 4,021 ​ ​ 4,533 Sales and marketing ​ ​ 285 ​ ​ 209 ​ ​ 593 ​ ​ 1,251 General and administrative ​ ​ 12,228 ​ ​ 4,292 ​ ​ 20,517 ​ ​ 14,833 Discontinued operations ​ ​ 1,858 ​ ​ 1,110 ​ ​ 4,364 ​ ​ 4,862 Total stock-based compensation expense ​ $ 17,236 ​ $ 8,011 ​ $ 32,537 ​ $ 28,962

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2022
Fair Value Measurements
Schedule of assets measured at fair value on a recurring basis	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurement ​ ​ at Reporting Date Using ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance as of ​ Level 1 Level 2 Level 3 September 30, 2022 Assets ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Contingent consideration receivable - long-term ​ $ — ​ $ — ​ $ 7,000 ​ $ 7,000
Schedule of financial instruments not carried at fair value	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Face Value Carrying Value Fair Value 1.75% Convertible Senior Subordinated Notes due 2026 ​ $ 325,000 ​ $ 320,297 ​ $ 258,131

Segment Reporting (Tables)

Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2022
Segment Reporting
Schedule of reportable operating segment information	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ CareVention HealthCare ​ Shared Services and Other ​ Consolidated Revenue: ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ Product revenue ​ $ 59,780 ​ $ — ​ $ 59,780 Service revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ PACE solutions ​ ​ 16,416 ​ ​ — ​ ​ 16,416 Medication safety services ​ ​ — ​ ​ 843 ​ ​ 843 Software subscription and services ​ ​ — ​ ​ 62 ​ ​ 62 Total service revenue ​ ​ 16,416 ​ ​ 905 ​ ​ 17,321 Total revenue ​ $ 76,196 ​ $ 905 ​ $ 77,101 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ Product revenue ​ $ 50,321 ​ $ — ​ $ 50,321 Service revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ PACE solutions ​ ​ 14,707 ​ ​ — ​ ​ 14,707 Medication safety services ​ ​ — ​ ​ 2,820 ​ ​ 2,820 Software subscription and services ​ ​ — ​ ​ 62 ​ ​ 62 Total service revenue ​ ​ 14,707 ​ ​ 2,882 ​ ​ 17,589 Total revenue ​ $ 65,028 ​ $ 2,882 ​ $ 67,910 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ Product revenue ​ $ 166,645 ​ $ — ​ $ 166,645 Service revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ PACE solutions ​ ​ 47,604 ​ ​ — ​ ​ 47,604 Medication safety services ​ ​ — ​ ​ 2,336 ​ ​ 2,336 Software subscription and services ​ ​ — ​ ​ 223 ​ ​ 223 Total service revenue ​ ​ 47,604 ​ ​ 2,559 ​ ​ 50,163 Total revenue ​ $ 214,249 ​ $ 2,559 ​ $ 216,808 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ Product revenue ​ $ 139,021 ​ $ — ​ $ 139,021 Service revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ PACE solutions ​ ​ 42,973 ​ ​ — ​ ​ 42,973 Medication safety services ​ ​ — ​ ​ 8,817 ​ ​ 8,817 Software subscription and services ​ ​ — ​ ​ 174 ​ ​ 174 Total service revenue ​ ​ 42,973 ​ ​ 8,991 ​ ​ 51,964 Total revenue ​ $ 181,994 ​ $ 8,991 ​ $ 190,985 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ CareVention HealthCare ​ Shared Services and Other ​ Consolidated Adjusted EBITDA (loss) from Continuing Operations: ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjusted EBITDA (loss) ​ $ 14,051 ​ $ (11,998) ​ $ 2,053 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjusted EBITDA (loss) ​ $ 14,014 ​ $ (10,875) ​ $ 3,139 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjusted EBITDA (loss) ​ $ 39,531 ​ $ (34,339) ​ $ 5,192 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjusted EBITDA (loss) ​ $ 40,983 ​ $ (32,998) ​ $ 7,985
Schedules of reconciliation of net loss to Adjusted EBITDA	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ 2022 2021 2022 2021 Reconciliation of Net Loss to Adjusted EBITDA from Continuing Operations ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss ​ $ (40,065) ​ $ (17,111) ​ $ (117,868) ​ $ (57,684) Add: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Interest expense, net ​ ​ 2,717 ​ ​ 2,230 ​ ​ 7,430 ​ ​ 6,959 Income tax (benefit) expense ​ ​ (7) ​ ​ 82 ​ ​ 368 ​ ​ 284 Depreciation and amortization ​ ​ 5,723 ​ ​ 5,328 ​ ​ 16,954 ​ ​ 15,109 Impairment charges ​ ​ — ​ ​ — ​ ​ 4,062 ​ ​ — Business optimization expenses ​ ​ — ​ ​ — ​ ​ 787 ​ ​ — Severance costs ​ ​ 122 ​ ​ 354 ​ ​ 697 ​ ​ 516 Executive transition ​ ​ 1,821 ​ ​ — ​ ​ 1,971 ​ ​ — Cooperation agreement costs ​ ​ 1,122 ​ ​ — ​ ​ 1,122 ​ ​ — Divestiture-related expense ​ ​ 1,057 ​ ​ — ​ ​ 2,591 ​ ​ — Acquisition-related expense ​ ​ — ​ ​ — ​ ​ — ​ ​ 217 Stock-based compensation expense ​ ​ 15,378 ​ ​ 6,901 ​ ​ 28,173 ​ ​ 24,100 Loss from discontinued operations ​ ​ 14,185 ​ ​ 5,355 ​ ​ 58,905 ​ ​ 18,484 Adjusted EBITDA from continuing operations ​ $ 2,053 ​ $ 3,139 ​ $ 5,192 ​ $ 7,985 Adjusted EBITDA (loss) from discontinued operations ​ ​ (3,593) ​ ​ 2,578 ​ ​ (1,036) ​ ​ 7,294 Total Adjusted EBITDA (loss) ​ $ (1,540) ​ $ 5,717 ​ $ 4,156 ​ $ 15,279 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ 2022 2021 2022 2021 Reconciliation of Net Loss from Discontinued Operations, net of tax to Adjusted EBITDA (Loss) from Discontinued Operations ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss from discontinued operations, net of tax ​ $ (14,185) ​ $ (5,355) ​ $ (58,905) ​ $ (18,484) Add: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Income tax (benefit) expense ​ ​ (94) ​ ​ 52 ​ ​ (662) ​ ​ 182 Depreciation and amortization ​ ​ — ​ ​ 6,771 ​ ​ 7,331 ​ ​ 20,234 Impairment charges ​ ​ 5,845 ​ ​ — ​ ​ 42,293 ​ ​ — Loss on disposal of business ​ ​ 2,879 ​ ​ — ​ ​ 2,879 ​ ​ — Settlement ​ ​ — ​ ​ — ​ ​ 1,448 ​ ​ 500 Divestiture-related expense ​ ​ 104 ​ ​ — ​ ​ 216 ​ ​ — Stock-based compensation expense ​ ​ 1,858 ​ ​ 1,110 ​ ​ 4,364 ​ ​ 4,862 Adjusted EBITDA (loss) from discontinued operations ​ $ (3,593) ​ $ 2,578 ​ $ (1,036) ​ $ 7,294

Basis of Presentation, Summar_3

Basis of Presentation, Summary of Significant Accounting Policies, and Recent Accounting Pronouncements - Cloud Computing Arrangements (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Other assets
Accumulated amortization, cloud computing implementation costs	$ 554		$ 554		$ 398
Amortization expense, cloud computing implementation costs	51	$ 53	156	$ 155
Prepaid expenses
Other assets
Capitalized cloud computing implementation costs	882		882		747
Other assets
Other assets
Capitalized cloud computing implementation costs	$ 1,276		$ 1,276		$ 0

Basis of Presentation, Summar_4

Basis of Presentation, Summary of Significant Accounting Policies, and Recent Accounting Pronouncements - Vendor Financing Arrangements (Details) - Business process support and technology services partner $ in Thousands		3 Months Ended	9 Months Ended
	Feb. 24, 2022 USD ($) employee	Sep. 30, 2022 USD ($)	Sep. 30, 2022 USD ($)
Financing Arrangements
Number of Company employees hired by third-party provider. | employee	180
Term of business partnership agreement.	7 years
Total estimated fees under business partnership agreement	$ 115,300
Vendor Financing Arrangements, Imputed interest rate (as a percent)	9.50%
Vendor Financing Arrangements, Non-cash interest expense		$ 53	$ 89
Accrued expenses and other liabilities, Current and noncurrent
Financing Arrangements
Vendor Financing Arrangements, Outstanding principal balance		3,772	3,772
Vendor Financing Arrangements, Unamortized discount		$ 876	$ 876

Basis of Presentation, Summar_5

Basis of Presentation, Summary of Significant Accounting Policies, and Recent Accounting Pronouncements - Concentrations (Details) - customer			3 Months Ended		9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Concentration Risk
Electronic payment term of claims					14 days
Nonelectronic payment term of claims					30 days
Client Claims Receivable | Credit risk
Concentration Risk
Number of clients		2
Client Claims Receivable | Credit risk | Client One
Concentration Risk
Number of clients	1
Concentration risk (as a percent)	21%	13%
Client Claims Receivable | Credit risk | Client Two
Concentration Risk
Concentration risk (as a percent)		11%
Revenue | Customer risk | Client One
Concentration Risk
Number of clients			1	1	1	1
Concentration risk (as a percent)			15%	13%	16%	14%

Discontinued Operations - Dives

Discontinued Operations - Divestiture of Business (Details) - USD ($) $ in Thousands			3 Months Ended	6 Months Ended	9 Months Ended
		Aug. 01, 2022	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2022	Oct. 31, 2022
Discontinued Operations
Contingent consideration receivable		$ 7,000	$ 7,000		$ 7,000
Loss on divestiture of business					2,879
Proceeds from sale of business	[1]				118,561
Other income			479		479
TDS | Transition Services Agreement
Discontinued Operations
Other income			$ 479		479
PrescribeWellness business and KD assets | Discontinued Operations, Disposed of by Sale
Discontinued Operations
Cash consideration received		125,000
PrescribeWellness business | Subsequent Event.
Discontinued Operations
Amount of cash received for certain adjustments related to net working capital subsequent to date of sale						$ 1,477
PrescribeWellness business | Discontinued Operations, Disposed of by Sale
Discontinued Operations
Cash consideration received		118,561
Contingent consideration receivable		7,000
Loss on divestiture of business		2,879
Aggregate gain/(loss) including impairment					$ 11,379
PrescribeWellness business | Discontinued Operations, Disposed of by Sale | Subsequent Event.
Discontinued Operations
Amount of cash received for certain adjustments related to net working capital subsequent to date of sale						$ 1,477
PrescribeWellness business | Discontinued Operations, Disposed of by Sale | Maximum
Discontinued Operations
Contingent consideration receivable		15,000
PrescribeWellness business | Discontinued Operations, Held-for-sale
Discontinued Operations
Goodwill impairment				$ 12,145
Impairment charge on net assets held for sale				$ 8,500
KD assets | Discontinued Operations, Disposed of by Sale | KD
Discontinued Operations
Cash consideration received		$ 5,900
[1] The cash proceeds received from divestiture of business do not include $1,477 of additional consideration subsequently received by the Company in October 2022 due to customary post-closing adjustments or $3,000 of transaction costs incurred as of the sale date and expected to be paid in the fourth quarter of 2022. See Note 3 for additional information.

Discontinued Operations - Div_2

Discontinued Operations - Divestiture of Business, Assets and Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Aug. 01, 2022	Dec. 31, 2021
Current assets of discontinued operations
Total current assets of discontinued operations	$ 26,861		$ 14,511
Noncurrent assets of discontinued operations
Total noncurrent assets of discontinued operations			187,558
Current liabilities of discontinued operations
Total current liabilities of discontinued operations	$ 11,132		12,380
Noncurrent liabilities of discontinued operations
Total noncurrent liabilities of discontinued operations			3,573
PrescribeWellness business | Discontinued Operations, Disposed of by Sale
Current assets of discontinued operations
Accounts receivable, net		$ 5,020
Prepaid expenses and other assets		1,751
Property and equipment, net		371
Operating lease right-of-use assets		1,252
Software development costs, net		14,536
Goodwill		35,314
Intangible assets, net		81,504
Impairment of carrying value		(8,500)
Total current assets of discontinued operations		131,248
Current liabilities of discontinued operations
Operating lease liabilities		1,086
Accounts payable		491
Accrued expenses and other liabilities		2,754
Total current liabilities of discontinued operations		$ 4,331
PrescribeWellness business | Discontinued Operations, Held-for-sale
Current assets of discontinued operations
Accounts receivable, net			8,002
Prepaid expenses and other assets			1,038
Total current assets of discontinued operations			9,040
Noncurrent assets of discontinued operations
Property and equipment, net			412
Operating lease right-of-use assets			1,434
Software development costs, net			11,474
Goodwill			47,459
Intangible assets, net			84,617
Other assets			64
Total noncurrent assets of discontinued operations			145,460
Current liabilities of discontinued operations
Operating lease liabilities			620
Accounts payable			913
Accrued expenses and other liabilities			3,529
Total current liabilities of discontinued operations			5,062
Noncurrent liabilities of discontinued operations
Noncurrent operating lease liabilities			830
Other long-term liabilities			135
Total noncurrent liabilities of discontinued operations			$ 965

Discontinued Operations - Div_3

Discontinued Operations - Divestiture of Business, Results of Operations (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
	Aug. 01, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Loss from discontinued operations
Loss on divestiture of business				$ 2,879
Net loss from discontinued operations, net of tax		$ (14,185)	$ (5,355)	(58,905)	$ (18,484)
PrescribeWellness business | Discontinued Operations, Held-for-sale or Disposed of by Sale
Loss from discontinued operations
Revenue		2,537		19,306
Cost of revenue, exclusive of depreciation and amortization		1,229		7,747
Operating expenses		2,336		14,930
Impairment charges				20,645
Loss on divestiture of business		2,879		2,879
Loss from discontinued operations before income taxes		(3,907)		(26,895)
Income tax (benefit) expense		(11)		(299)
Net loss from discontinued operations, net of tax		$ (3,896)		$ (26,596)
PrescribeWellness business | Discontinued Operations, Disposed of by Sale
Loss from discontinued operations
Loss on divestiture of business	$ 2,879
PrescribeWellness business | Discontinued Operations, Held-for-sale
Loss from discontinued operations
Revenue			10,533		27,629
Cost of revenue, exclusive of depreciation and amortization			3,426		9,883
Operating expenses			8,373		24,427
Loss from discontinued operations before income taxes			(1,266)		(6,681)
Income tax (benefit) expense			12		66
Net loss from discontinued operations, net of tax			$ (1,278)		$ (6,747)

Discontinued Operations - Div_4

Discontinued Operations - Divestiture of Business, Operating non-cash items and investing activities (Details) - USD ($) $ in Thousands		3 Months Ended	9 Months Ended
	Aug. 01, 2022	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2021
Operating non-cash items and investing activities of discontinued operations:
Loss on divestiture of business			$ 2,879
PrescribeWellness business | Discontinued Operations, Held-for-sale or Disposed of by Sale
Operating non-cash items and investing activities of discontinued operations:
Depreciation and amortization			4,551
Impairment charges			20,645
Stock-based compensation			1,697
Loss on divestiture of business		$ 2,879	2,879
Purchases of property and equipment			(22)
Software development costs			$ (4,443)
PrescribeWellness business | Discontinued Operations, Disposed of by Sale
Operating non-cash items and investing activities of discontinued operations:
Loss on divestiture of business	$ 2,879
PrescribeWellness business | Discontinued Operations, Held-for-sale
Operating non-cash items and investing activities of discontinued operations:
Depreciation and amortization				$ 12,059
Stock-based compensation				2,352
Purchases of property and equipment				(305)
Software development costs				$ (9,783)

Discontinued Operations - Held

Discontinued Operations - Held for Sale (Details) - USD ($) $ in Thousands		3 Months Ended	9 Months Ended
		Sep. 30, 2022	Sep. 30, 2022
Discontinued Operations
Proceeds from sale of business	[1]		$ 118,561
DoseMe and SinfonaRx businesses
Discontinued Operations
Period within which sale is highly probable			1 year
DoseMe and SinfonaRx businesses | Discontinued Operations, Held-for-sale
Discontinued Operations
Goodwill impairment		$ 0	$ 6,127
Impairment charge on net assets held for sale		$ 5,845	$ 15,521
[1] The cash proceeds received from divestiture of business do not include $1,477 of additional consideration subsequently received by the Company in October 2022 due to customary post-closing adjustments or $3,000 of transaction costs incurred as of the sale date and expected to be paid in the fourth quarter of 2022. See Note 3 for additional information.

Discontinued Operations - Hel_2

Discontinued Operations - Held for Sale, Results of Operations (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Loss from discontinued operations
Net loss from discontinued operations, net of tax	$ (14,185)	$ (5,355)	$ (58,905)	$ (18,484)
DoseMe and SinfonaRx businesses | Discontinued Operations, Held-for-sale
Loss from discontinued operations
Revenue	6,407	8,143	23,094	26,961
Cost of revenue, exclusive of depreciation and amortization	7,055	6,521	20,479	19,755
Operating expenses	3,879	5,659	13,639	18,827
Impairment charges	5,845		21,648
Loss from discontinued operations before income taxes	(10,372)	(4,037)	(32,672)	(11,621)
Income tax (benefit) expense	(83)	40	(363)	116
Net loss from discontinued operations, net of tax	$ (10,289)	$ (4,077)	$ (32,309)	$ (11,737)

Discontinued Operations - Hel_3

Discontinued Operations - Held for Sale, Assets and Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets of discontinued operations
Total current assets of discontinued operations	$ 26,861	$ 14,511
Noncurrent assets of discontinued operations
Total noncurrent assets of discontinued operations		187,558
Current liabilities of discontinued operations
Total current liabilities of discontinued operations	11,132	12,380
Noncurrent liabilities of discontinued operations
Total noncurrent liabilities of discontinued operations		3,573
DoseMe and SinfonaRx businesses | Discontinued Operations, Held-for-sale
Current assets of discontinued operations
Cash	69	273
Accounts receivable, net	4,964	4,644
Prepaid expenses and other assets	796	554
Property and equipment, net	1,349
Operating lease right-of-use assets	3,732
Software development costs, net	6,910
Goodwill	1,927
Intangible assets, net	22,635
Impairment of carrying value	(15,521)
Total current assets of discontinued operations	26,861	5,471
Noncurrent assets of discontinued operations
Property and equipment, net		1,485
Operating lease right-of-use assets		3,296
Software development costs, net		4,466
Goodwill		8,053
Intangible assets, net		24,675
Other assets		123
Total noncurrent assets of discontinued operations		42,098
Current liabilities of discontinued operations
Operating lease liabilities	3,458	793
Accounts payable	3,077	3,395
Accrued expenses and other liabilities	4,597	3,130
Total current liabilities of discontinued operations	$ 11,132	7,318
Noncurrent liabilities of discontinued operations
Noncurrent operating lease liabilities		2,608
Total noncurrent liabilities of discontinued operations		$ 2,608

Discontinued Operations - Hel_4

Discontinued Operations - Held for Sale, Operating non-cash items and investing activities (Details) - DoseMe and SinfonaRx businesses - Discontinued Operations, Held-for-sale - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2021
Operating non-cash items and investing activities of discontinued operations:
Depreciation and amortization		$ 2,780	$ 8,175
Impairment charges	$ 5,845	21,648
Stock-based compensation		2,667	2,510
Purchases of property and equipment		(50)	(1,323)
Software development costs		$ (2,998)	$ (6,155)

Revenue - General (Details)

Revenue - General (Details)	9 Months Ended
	Sep. 30, 2022
Minimum
Contract with customer
Client contract term	1 year
Termination notice period	0 days
Maximum
Contract with customer
Client contract term	5 years
Termination notice period	180 days

Revenue - Disaggregation (Detai

Revenue - Disaggregation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Disaggregation of revenue
Total revenue	$ 77,101	$ 67,910	$ 216,808	$ 190,985
Product
Disaggregation of revenue
Total revenue	59,780	50,321	166,645	139,021
Service
Disaggregation of revenue
Total revenue	17,321	17,589	50,163	51,964
Service - PACE solutions
Disaggregation of revenue
Total revenue	16,416	14,707	47,604	42,973
Service - Medication safety services
Disaggregation of revenue
Total revenue	843	2,820	2,336	8,817
Service - Software subscription and services
Disaggregation of revenue
Total revenue	62	62	223	174
CareVention HealthCare
Disaggregation of revenue
Total revenue	76,196	65,028	214,249	181,994
CareVention HealthCare | Product
Disaggregation of revenue
Total revenue	59,780	50,321	166,645	139,021
CareVention HealthCare | PACE product revenue
Disaggregation of revenue
Total revenue	59,780	50,321	166,645	139,021
CareVention HealthCare | Service
Disaggregation of revenue
Total revenue	16,416	14,707	47,604	42,973
CareVention HealthCare | Service - PACE solutions
Disaggregation of revenue
Total revenue	16,416	14,707	47,604	42,973
MedWise HealthCare
Disaggregation of revenue
Total revenue	905	2,882	2,559	8,991
MedWise HealthCare | Service - Medication safety services
Disaggregation of revenue
Total revenue	843	2,820	2,336	8,817
MedWise HealthCare | Service - Software subscription and services
Disaggregation of revenue
Total revenue	$ 62	$ 62	$ 223	$ 174

Revenue - Contract Balances (De

Revenue - Contract Balances (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Contract Balances
Contract assets	$ 15,072	$ 12,695
Contract liabilities	$ 4,110	$ 2,191	$ 1,982

Revenue - Change in contract ba

Revenue - Change in contract balances (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Contract assets:
Contract assets, beginning of period	$ 12,695
Decreases due to cash received	(12,466)
Changes to the contract assets at the beginning of the period as a result of changes in estimates	451
Changes during the year, net of reclassifications to receivables	14,392
Contract assets, end of period	15,072
Contract liabilities:
Contract liabilities, beginning of period	2,191	$ 1,982
Revenue recognized that was included in the contract liabilities balance at the beginning of the period	(1,903)	$ (1,404)
Increases due to cash received, excluding amounts recognized as revenue during the period	3,822
Contract liabilities, end of period	$ 4,110

Net Loss per Share - EPS (Detai

Net Loss per Share - EPS (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Numerator (basic and diluted):
Net loss from continuing operations, basic	$ (25,880)	$ (11,756)	$ (58,963)	$ (39,200)
Net loss from discontinued operations, basic	(14,185)	(5,355)	(58,905)	(18,484)
Net loss, basic	(40,065)	(17,111)	(117,868)	(57,684)
Net loss from continuing operations, diluted	(25,880)	(11,756)	(58,963)	(39,200)
Net loss from discontinued operations, diluted	(14,185)	(5,355)	(58,905)	(18,484)
Net loss, diluted	$ (40,065)	$ (17,111)	$ (117,868)	$ (57,684)
Denominator (basic and diluted):
Weighted average common shares outstanding, basic (in shares)	24,350,182	23,407,391	24,075,666	23,230,138
Weighted average common shares outstanding, diluted (in shares)	24,350,182	23,407,391	24,075,666	23,230,138
Net loss per share from continuing operations, basic (in dollars per share)	$ (1.07)	$ (0.50)	$ (2.45)	$ (1.68)
Net loss per share from discontinued operations, basic (in dollars per share)	(0.58)	(0.23)	(2.45)	(0.80)
Total net loss per share, basic (in dollars per share)	(1.65)	(0.73)	(4.90)	(2.48)
Net loss per share from continuing operations, diluted (in dollars per share)	(1.07)	(0.50)	(2.45)	(1.68)
Net loss per share from discontinued operations, diluted (in dollars per share)	(0.58)	(0.23)	(2.45)	(0.80)
Total net loss per share, diluted (in dollars per share)	$ (1.65)	$ (0.73)	$ (4.90)	$ (2.48)

Net Loss per Share - Anti-dilut

Net Loss per Share - Anti-dilutive Securities (Details) - shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Securities excluded from the calculation of diluted net loss per share attributable to common stockholders
Amount of antidilutive securities excluded from computation of earnings per share	12,912,750	12,588,989
Stock options
Securities excluded from the calculation of diluted net loss per share attributable to common stockholders
Amount of antidilutive securities excluded from computation of earnings per share	1,402,931	1,671,680
Restricted stock and restricted stock units
Securities excluded from the calculation of diluted net loss per share attributable to common stockholders
Amount of antidilutive securities excluded from computation of earnings per share	2,217,033	1,624,523
Common stock warrants/Convertible note warrants
Securities excluded from the calculation of diluted net loss per share attributable to common stockholders
Amount of antidilutive securities excluded from computation of earnings per share	4,646,393	4,646,393
Convertible Debt
Securities excluded from the calculation of diluted net loss per share attributable to common stockholders
Amount of antidilutive securities excluded from computation of earnings per share	4,646,393	4,646,393

Other Current Assets (Details)

Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Other Current Assets
Contract assets	$ 15,072	$ 12,695
Non-trade receivables	1,235	3,289
Divestiture related consideration receivables	1,477
Other	2,655	2,049
Total other current assets	$ 20,439	$ 18,033

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Property and Equipment
Property and equipment, net	$ 10,038		$ 10,038		$ 11,778
Depreciation and amortization	5,723	$ 5,328	16,954	$ 15,109
Property and equipment
Property and Equipment
Accumulated depreciation	18,890		18,890		$ 17,427
Depreciation and amortization	$ 801	$ 825	$ 2,862	$ 2,672

Software Development Costs (Det

Software Development Costs (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Software Development Costs
Software development costs	$ 51,305		$ 51,305		$ 49,481
Less: accumulated amortization	(18,699)		(18,699)		(20,227)
Software development costs, net	32,606		32,606		29,254
Capitalized software development costs included above not yet subject to amortization	4,505		4,505		$ 5,328
Amortization expense	$ 3,224	$ 2,579	9,005	$ 6,682
Long-lived asset impairment charge			$ 4,062

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Goodwill (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Goodwill and related changes
Goodwill	$ 115,323	$ 115,323

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Intangible assets (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Intangible Assets
Gross Value	$ 69,023		$ 69,023		$ 69,023
Accumulated Amortization	(28,748)		(28,748)		(23,665)
Intangible Assets, net	40,275		40,275		$ 45,358
Amortization expense	1,694	$ 1,907	$ 5,083	$ 5,738
Trade name
Intangible Assets
Weighted Average Amortization Period			2 years 7 months 6 days		2 years 10 months 24 days
Gross Value	1,340		$ 1,340		$ 1,340
Accumulated Amortization	(982)		(982)		(853)
Intangible Assets, net	358		$ 358		$ 487
Client relationships
Intangible Assets
Weighted Average Amortization Period			11 years 8 months 12 days		11 years 8 months 12 days
Gross Value	51,264		$ 51,264		$ 51,264
Accumulated Amortization	(14,438)		(14,438)		(11,042)
Intangible Assets, net	36,826		$ 36,826		$ 40,222
Non-competition agreements
Intangible Assets
Weighted Average Amortization Period			5 years		5 years
Gross Value	1,640		$ 1,640		$ 1,640
Accumulated Amortization	(1,221)		(1,221)		(975)
Intangible Assets, net	419		$ 419		$ 665
Developed technology
Intangible Assets
Weighted Average Amortization Period			6 years 2 months 12 days		6 years 2 months 12 days
Gross Value	14,720		$ 14,720		$ 14,720
Accumulated Amortization	(12,076)		(12,076)		(10,768)
Intangible Assets, net	2,644		$ 2,644		$ 3,952
Domain name
Intangible Assets
Weighted Average Amortization Period			10 years		10 years
Gross Value	59		$ 59		$ 59
Accumulated Amortization	(31)		(31)		(27)
Intangible Assets, net	$ 28		$ 28		$ 32

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Amortization (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Estimated amortization expense
2022 (October 1 - December 31)	$ 1,669
2023	6,162
2024	4,684
2025	4,466
2026	4,338
2027	4,271
Thereafter	14,685
Total estimated amortization expense	$ 40,275	$ 45,358

Accrued Expenses and Other Li_3

Accrued Expenses and Other Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Accrued Expenses and Other Liabilities
Employee related expenses	$ 8,961	$ 8,595
Contract liability	3,864	2,015
Customer deposits	903	904
Client funds obligations	7,389	6,038
Contract labor	2,852	838
Divestiture closing fees	3,000
Interest	711	2,281
Vendor financing arrangements	176
Professional fees	2,161	1,327
Consideration payable to customer	24,500	15,971
Income and non-income taxes payable	95	15
Other expenses	4,895	3,013
Total accrued expenses and other liabilities	$ 59,507	$ 40,997

Line of Credit and Long-Term _3

Line of Credit and Long-Term Debt - Line of Credit (Details) - USD ($) $ in Thousands			3 Months Ended		9 Months Ended
	Aug. 01, 2022	Dec. 18, 2020	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Lines of Credit
Repayment of line of credit					$ 57,200
2020 Credit Facility
Lines of Credit
Maximum borrowing capacity		$ 120,000
Sublimit of loan		$ 1,000
Commitment fee at closing (as a percent)		0.50%
Commitment fee payable on each anniversary (as a percent)		0.25%
Repayment of principal and interest	$ 57,406
Interest expense			$ 266	$ 314	1,363	$ 842
Deferred financing costs, gross			1,534		1,534
Amortization of deferred financing costs to interest expense			$ 698	$ 136	$ 973	$ 404
2020 Credit Facility | LIBOR
Lines of Credit
Spread on variable rate (as a percent)		3.25%

Line of Credit and Long-Term _4

Line of Credit and Long-Term Debt - Convertible Senior Subordinated Notes (Details) $ / shares in Units, $ in Thousands		3 Months Ended		9 Months Ended
	Feb. 12, 2019 USD ($) D $ / shares	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Lines of Credit and Long-Term Debt
Accrued interest payable		$ 711		$ 711		$ 2,281
Cash paid for interest				7,204	$ 8,169
Long term debt, net		320,297		320,297		$ 319,299
2026 Notes, Convertible Senior Subordinated Notes
Lines of Credit and Long-Term Debt
Aggregate borrowings	$ 325,000	$ 325,000		$ 325,000
Interest rate (as a percent)	1.75%	1.75%		1.75%
Initial conversion rate	0.0142966
Initial conversion price (in dollars per share) | $ / shares	$ 69.95
Principal amount	$ 1
Debt issuance costs	$ 9,372
Effective interest rate		2.20%		2.20%
Interest expense		$ 1,757	$ 1,750	$ 5,265	5,243
Paid or accrued interest		1,422	1,423	4,266	4,266
Non-cash accretion of discounts		335	327	999	977
Amount of additional interest payable			$ 212		$ 212
Accrued interest payable		711		711
Long term debt, net		$ 320,297		$ 320,297
2026 Notes, Convertible Senior Subordinated Notes | Debt Conversion Scenario One
Lines of Credit and Long-Term Debt
Trading days | D	20
Consecutive trading days | D	30
Stock price trigger percentage (as a percent)	130%
2026 Notes, Convertible Senior Subordinated Notes | Debt Conversion Scenario Two
Lines of Credit and Long-Term Debt
Trading days | D	5
Consecutive trading days | D	5
Principal amount	$ 1
Stock price trigger percentage (as a percent)	98%

Line of Credit and Long-Term _5

Line of Credit and Long-Term Debt - Convertible Note Hedge and Warrant Transactions (Details) - USD ($) $ / shares in Units, $ in Thousands		9 Months Ended
	Feb. 12, 2019	Sep. 30, 2022
Warrants and options indexed to Company's stock
Warrants exercised		0
Convertible senior subordinated notes, Option to purchase shares
Warrants and options indexed to Company's stock
Options indexed to Company's stock (in shares)	4,646,393
Price of options indexed to Company's stock (in dollars per share)	$ 105.58
Proceeds from sale of warrants	$ 65,910
Common stock warrants/Convertible note warrants
Warrants and options indexed to Company's stock
Option to purchase	4,646,393
Exercise price (in dollars per share)	$ 69.95
Premiums paid for the note hedges	$ 101,660

Line of Credit and Long-Term _6

Line of Credit and Long-Term Debt - Long-term debt (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Long-Term Debt
Unamortized discount, including debt issuance costs, on convertible senior subordinated notes	$ (4,703)	$ (5,701)
Total long-term debt, net	320,297	319,299
2026 Notes, Convertible Senior Subordinated Notes
Long-Term Debt
Total long-term debt, net	320,297
Convertible senior subordinated notes - excluding related party
Long-Term Debt
Convertible senior subordinated notes	235,272	$ 325,000
Convertible senior subordinated notes - related party
Long-Term Debt
Convertible senior subordinated notes	$ 89,728

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
	Feb. 12, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Taxes
Income tax (benefit) expense		$ (7)	$ 82	$ 368	$ 284
Effective tax rate (as a percent)		0%	(0.70%)	(0.60%)	(0.70%)
Increase in deferred tax asset	$ 26,313
Increase (decrease) valuation allowance	$ 26,313

Stock-Based Compensation - Plan

Stock-Based Compensation - Plans (Details) - 2016 Plan - shares		1 Months Ended
	Feb. 25, 2022	Sep. 30, 2016	Sep. 30, 2022
Stock-Based Compensation
Automatic increase on share reserve (as a percent)		5%
Additional shares authorized	1,283,321
Available for future grant (in shares)			1,123,371

Stock-Based Compensation - Rest

Stock-Based Compensation - Restricted Common Stock and Restricted Stock Units (Details) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022 USD ($) employee $ / shares shares	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) employee $ / shares shares	Sep. 30, 2021 USD ($)
Weighted average grant date fair value
Stock-based compensation expense, including discontinued operations (in dollars) | $	$ 17,236	$ 8,011	$ 32,537	$ 28,962
Restricted stock and restricted stock units
Weighted average grant date fair value
Stock-based compensation expense, including discontinued operations (in dollars) | $	13,061	$ 6,447	26,129	$ 22,846
Unrecognized compensation expense (in dollars) | $	$ 30,976		$ 30,976
Weighted average period expected to be recognized			2 years 4 months 24 days
Restricted stock and restricted stock units | Minimum
Stock-Based Compensation
Vesting period			1 year
Restricted stock and restricted stock units | Maximum
Stock-Based Compensation
Vesting period			4 years
Restricted stock, performance based restricted stock and restricted stock units
Number of shares
Outstanding at beginning of period (in shares)			2,196,566
Granted (in shares)			1,935,883
Vested (in shares)			(1,224,471)
Forfeited (in shares)			(676,723)
Outstanding at end of period (in shares)	2,231,255		2,231,255
Weighted average grant date fair value
Outstanding at beginning of period (in dollars per share) | $ / shares			$ 40.19
Granted (in dollars per share) | $ / shares			4.44
Vested (in dollars per share) | $ / shares			34.32
Forfeited (in dollars per share) | $ / shares			16.40
Outstanding at end of period (in dollars per share) | $ / shares	$ 19.61		$ 19.61
Restricted stock | Named executive officers
Weighted average grant date fair value
Accelerated vesting expense | $	$ 8,143		$ 8,143
Number of retired employees with accelerated vesting related to separation agreements | employee	2		2
Restricted stock units
Weighted average grant date fair value
Awards vested but not yet issued	14,222		14,222

Stock-Based Compensation - Perf

Stock-Based Compensation - Performance Based Equity Awards (Details) - USD ($) $ / shares in Units, $ in Thousands						3 Months Ended		9 Months Ended
	Aug. 22, 2022	Dec. 31, 2021	Apr. 30, 2021	Apr. 27, 2021	Oct. 29, 2020	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Stock-Based Compensation
Stock-based compensation expense, including discontinued operations (in dollars)						$ 17,236	$ 8,011	$ 32,537	$ 28,962
Award Date, August 22, 2022
Stock-Based Compensation
Number of target shares						350,000		350,000
Performance stock units | Award Date, October 29, 2020
Stock-Based Compensation
Granted (in shares)					26,400
Weighted average grant-date fair value (in dollars per share)					$ 35.95
Stock-based compensation expense, including discontinued operations (in dollars)							$ 194		$ 556
Expired (in shares)		12,500	1,400
Vested (in shares)		12,500
Performance stock units | Award Date, April 27, 2021
Stock-Based Compensation
Number of target shares						45,550		45,550
Vesting period				3 years
Weighted average grant-date fair value (in dollars per share)				$ 44.13
Expired (in shares)								47,175
Maximum number of achievable performance stock units						91,100		91,100
Performance stock units | Award Date, April 27, 2021 | Minimum
Stock-Based Compensation
Vesting (as a percent)				0%
Performance stock units | Award Date, April 27, 2021 | Maximum
Stock-Based Compensation
Vesting (as a percent)				200%
Unrecognized compensation expense (in dollars)						$ 4,020		$ 4,020
Performance stock units | Award Date, August 22, 2022
Stock-Based Compensation
Vesting period	3 years
Weighted average grant-date fair value (in dollars per share)	$ 4.38
Stock-based compensation expense, including discontinued operations (in dollars)						$ 69		$ 69
Maximum number of achievable performance stock units						700,000		700,000
Unrecognized compensation expense (in dollars)						$ 1,463		$ 1,463
Performance stock units | Award Date, August 22, 2022 | Minimum
Stock-Based Compensation
Vesting (as a percent)	0%
Performance stock units | Award Date, August 22, 2022 | Maximum
Stock-Based Compensation
Vesting (as a percent)	200%

Stock-Based Compensation - Othe

Stock-Based Compensation - Other Stock Awards (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended					9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Stock-Based Compensation
Stock-based compensation expense, including discontinued operations (in dollars)	$ 17,236			$ 8,011		$ 32,537	$ 28,962
Other stock awards | Award Date, First Quarter, 2021
Stock-Based Compensation
Issuance of common stock awards (in shares)					1,416
Weighted average grant-date fair value (in dollars per share)					$ 40.85
Stock-based compensation expense, including discontinued operations (in dollars)							$ 58
Other stock awards | Award Date, First Quarter, 2022
Stock-Based Compensation
Issuance of common stock awards (in shares)			16,471
Weighted average grant-date fair value (in dollars per share)			$ 5.57
Stock-based compensation expense, including discontinued operations (in dollars)						92
Other stock awards | Award Date, Second Quarter, 2022
Stock-Based Compensation
Issuance of common stock awards (in shares)		12,262
Weighted average grant-date fair value (in dollars per share)		$ 3.64
Stock-based compensation expense, including discontinued operations (in dollars)						45
Other stock awards | Award Date, Third Quarter, 2022
Stock-Based Compensation
Issuance of common stock awards (in shares)	615,066
Weighted average grant-date fair value (in dollars per share)	$ 5.01
Stock-based compensation expense, including discontinued operations (in dollars)	$ 3,081					$ 3,081

Stock-Based Compensation - Opti

Stock-Based Compensation - Options Valuation (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Stock-Based Compensation
Stock-based compensation expense, including discontinued operations (in dollars)	$ 17,236	$ 8,011	$ 32,537	$ 28,962
Options granted (in shares)			0
Stock options
Stock-Based Compensation
Stock-based compensation expense, including discontinued operations (in dollars)	$ 1,025	$ 1,586	$ 3,121	$ 5,502
Valuation assumptions:
Expected volatility (as a percent)				58.57%
Expected term (years)				5 years 5 months 23 days
Risk-free interest rate (as a percent)				0.50%
Weighted average grant-date fair value (in dollars per share)				$ 28.26

Stock-Based Compensation - Op_2

Stock-Based Compensation - Options Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2021
Number of shares
Outstanding at beginning of period (in shares)		1,604,226
Exercised (in shares)		(12,830)
Forfeited (in shares)		(188,465)
Outstanding at end of the period (in shares)	1,402,931	1,402,931
Options vested and expected to vest at end of the period (in shares)	1,402,931	1,402,931
Exercisable at end of period (in shares)	1,370,302	1,370,302
Weighted average exercise price
Outstanding at beginning of period (in dollars per share)		$ 29.90
Exercised (in dollars per share)		4.96
Forfeited (in dollars per share)		44.18
Outstanding at end of period (in dollars per share)	$ 28.21	28.21
Options vested and expected to vest at end of period (in dollars per share)	28.21	28.21
Exercisable at end of period (in dollars per share)	$ 27.57	$ 27.57
Weighted average remaining contractual term
Outstanding		3 years 9 months 18 days
Options vested and expected to vest at of the period		3 years 9 months 18 days
Exercisable		3 years 9 months 18 days
Aggregate intrinsic value
Outstanding (in dollars)	$ 260	$ 260
Options vested and expected to vest at end of period (in dollars)	260	260
Exercisable (in dollars)	260	260
Additional disclosures
Intrinsic value of options exercised (in dollars)		109	$ 11,113
Proceeds from stock options exercised (in dollars)		64	$ 3,683
Shares paid for tax withholding, fair value	2,140
Stock options
Additional disclosures
Unrecognized compensation cost (in dollars)	$ 867	$ 867
Weighted average period expected to be recognized		4 months 24 days

Stock-Based Compensation - Expe

Stock-Based Compensation - Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Stock-based compensation expense
Stock-based compensation expense, including discontinued operations (in dollars)	$ 17,236	$ 8,011	$ 32,537	$ 28,962
Cost of revenue - product
Stock-based compensation expense
Stock-based compensation expense, including discontinued operations (in dollars)	331	256	778	852
Cost of revenue - service
Stock-based compensation expense
Stock-based compensation expense, including discontinued operations (in dollars)	793	883	2,264	2,631
Research and development
Stock-based compensation expense
Stock-based compensation expense, including discontinued operations (in dollars)	1,741	1,261	4,021	4,533
Sales and marketing
Stock-based compensation expense
Stock-based compensation expense, including discontinued operations (in dollars)	285	209	593	1,251
General and administrative
Stock-based compensation expense
Stock-based compensation expense, including discontinued operations (in dollars)	12,228	4,292	20,517	14,833
Discontinued operations
Stock-based compensation expense
Stock-based compensation expense, including discontinued operations (in dollars)	$ 1,858	$ 1,110	$ 4,364	$ 4,862

Stock-Based Compensation - Empl

Stock-Based Compensation - Employee Stock Purchase Plan (Details) - Employee Stock Purchase Plan	Sep. 30, 2022 shares
Stock-Based Compensation
Discount (as a percent)	15%
Number of shares reserved for issuance	480,097

Fair Value Measurements - Finan

Fair Value Measurements - Financial Instruments (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Aug. 01, 2022	Feb. 12, 2019
Fair Value Measurements
Contingent consideration receivable	$ 7,000	$ 7,000
Level 3
Fair Value Measurements
Contingent consideration receivable	$ 7,000
2026 Notes, Convertible Senior Subordinated Notes
Fair Value Measurements
Interest rate (as a percent)	1.75%		1.75%
Face value	$ 325,000		$ 325,000
2026 Notes, Convertible Senior Subordinated Notes | Carrying Value
Fair Value Measurements
Debt instrument	320,297
2026 Notes, Convertible Senior Subordinated Notes | Fair Value
Fair Value Measurements
Debt instrument	$ 258,131

Commitments and Contingencies -

Commitments and Contingencies - Vendor Purchase Agreements (Details) - USD ($) $ in Thousands	Jan. 01, 2020	Mar. 29, 2019	Sep. 30, 2022	Dec. 31, 2021	Nov. 30, 2021	Nov. 01, 2021	Oct. 31, 2021	Jun. 30, 2021
Thrifty Drug Stores, Inc.
Purchase Agreements
Purchase obligation (as a percent)		98%
Amount due as a result of prescription drug purchases			$ 1,993	$ 1,854
Data aggregation partner
Purchase Agreements
Purchase obligation period	3 years
Monthly minimum purchase obligation	$ 30
Cloud hosting and support services provider under October 2021 agreement
Purchase Agreements
Minimum purchase obligation							$ 7,050
Remaining commitment			4,700
Cloud hosting and support services provider under June 2021 agreement
Purchase Agreements
Minimum purchase obligation								$ 1,272
Remaining commitment			691
Enterprise support and information technology services provider
Purchase Agreements
Minimum purchase obligation						$ 8,960
Remaining commitment			6,222
Cloud hosting services provider
Purchase Agreements
Minimum purchase obligation					$ 1,598
Remaining commitment			$ 243

Segment Reporting - Revenue (De

Segment Reporting - Revenue (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) segment	Sep. 30, 2021 USD ($)
Segment Reporting
Number of operating segment | segment			2
Total revenue	$ 77,101	$ 67,910	$ 216,808	$ 190,985
Product
Segment Reporting
Total revenue	59,780	50,321	166,645	139,021
Service
Segment Reporting
Total revenue	17,321	17,589	50,163	51,964
Service - PACE solutions
Segment Reporting
Total revenue	16,416	14,707	47,604	42,973
Service - Medication safety services
Segment Reporting
Total revenue	843	2,820	2,336	8,817
Service - Software subscription and services
Segment Reporting
Total revenue	62	62	223	174
CareVention HealthCare
Segment Reporting
Total revenue	76,196	65,028	214,249	181,994
CareVention HealthCare | Product
Segment Reporting
Total revenue	59,780	50,321	166,645	139,021
CareVention HealthCare | Service
Segment Reporting
Total revenue	16,416	14,707	47,604	42,973
CareVention HealthCare | Service - PACE solutions
Segment Reporting
Total revenue	16,416	14,707	47,604	42,973
Shared Services and Other
Segment Reporting
Total revenue	905	2,882	2,559	8,991
Shared Services and Other | Service
Segment Reporting
Total revenue	905	2,882	2,559	8,991
Shared Services and Other | Service - Medication safety services
Segment Reporting
Total revenue	843	2,820	2,336	8,817
Shared Services and Other | Service - Software subscription and services
Segment Reporting
Total revenue	$ 62	$ 62	$ 223	$ 174

Segment Reporting - EBITDA (Det

Segment Reporting - EBITDA (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Segment Reporting
Adjusted EBITDA (loss) from continuing operations	$ 2,053	$ 3,139	$ 5,192	$ 7,985
Shared Services and Others
Segment Reporting
Adjusted EBITDA (loss) from continuing operations	(11,998)	(10,875)	(34,339)	(32,998)
CareVention HealthCare | Operating Segments
Segment Reporting
Adjusted EBITDA (loss) from continuing operations	$ 14,051	$ 14,014	$ 39,531	$ 40,983

Segment Reporting - Reconciliat

Segment Reporting - Reconciliation of Net Loss to Adjusted EBITDA (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Reconciliation of Net Loss to Adjusted EBITDA from Continuing Operations
Net loss	$ (40,065)	$ (49,610)	$ (28,193)	$ (17,111)	$ (21,081)	$ (19,492)	$ (117,868)	$ (57,684)
Interest expense, net	2,717			2,230			7,430	6,959
Income tax (benefit) expense	(7)			82			368	284
Depreciation and amortization	5,723			5,328			16,954	15,109
Impairment charges							4,062
Business optimization expenses							787
Severance costs	122			354			697	516
Executive transition	1,821						1,971
Cooperation agreement costs	1,122						1,122
Divestiture-related expense	1,057						2,591
Acquisition-related expense								217
Stock- based compensation expense	15,378			6,901			28,173	24,100
Loss from discontinued operations	14,185			5,355			58,905	18,484
Adjusted EBITDA from continuing operations	2,053			3,139			5,192	7,985
Adjusted EBITDA (loss) from discontinued operations	(3,593)			2,578			(1,036)	7,294
Total Adjusted EBITDA (loss)	$ (1,540)			$ 5,717			$ 4,156	$ 15,279

Segment Reporting - Reconcili_2

Segment Reporting - Reconciliation of Net Loss to Adjusted EBITDA (Loss), Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Reconciliation of Net Loss from Discontinued Operations, net of tax to Adjusted EBITDA from Discontinued Operations
Net loss from discontinued operations, net of tax	$ (14,185)	$ (5,355)	$ (58,905)	$ (18,484)
Loss on divestiture of business			2,879
Adjusted EBITDA (loss) from discontinued operations	(3,593)	2,578	(1,036)	7,294
DoseMe, SinfonaRx and PrescribeWellness businesses | Discontinued Operations, Held-for-sale or Disposed of by Sale
Reconciliation of Net Loss from Discontinued Operations, net of tax to Adjusted EBITDA from Discontinued Operations
Net loss from discontinued operations, net of tax	(14,185)		(58,905)
Income tax (benefit) expense	(94)		(662)
Depreciation and amortization			7,331
Impairment charges	5,845		42,293
Loss on divestiture of business	2,879		2,879
Settlement			1,448
Divestiture-related expense	104		216
Stock-based compensation expense	1,858		4,364
Adjusted EBITDA (loss) from discontinued operations	$ (3,593)		$ (1,036)
DoseMe, SinfonaRx and PrescribeWellness businesses | Discontinued Operations, Held-for-sale
Reconciliation of Net Loss from Discontinued Operations, net of tax to Adjusted EBITDA from Discontinued Operations
Net loss from discontinued operations, net of tax		(5,355)		(18,484)
Income tax (benefit) expense		52		182
Depreciation and amortization		6,771		20,234
Settlement				500
Stock-based compensation expense		1,110		4,862
Adjusted EBITDA (loss) from discontinued operations		$ 2,578		$ 7,294

Related Party Transactions (Det

Related Party Transactions (Details) $ in Thousands		3 Months Ended		9 Months Ended
	Sep. 13, 2022 item	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Related Party Transactions
Convertible senior subordinated notes held by a significant stockholder		$ 88,429		$ 88,429
Pharmacy services and PACE solutions services
Related Party Transactions
Revenue from related party		1,894	$ 1,679	5,541	$ 4,834
Pharmacy services and PACE solutions services | Accounts receivable, net
Related Party Transactions
Accounts receivable from related parties		225		225		$ 67
Cooperation Agreement
Related Party Transactions
Amount due to related party		464		464
Separation Agreements
Related Party Transactions
Amount due to related party		1,616		1,616
Number of former executive officers under the agreement | item	2
General and administrative expenses		9,927
Consultant Services Agreements
Related Party Transactions
Number of former executive officers under the agreement | item	2
General and administrative expenses		$ 0		$ 0

Rights Plan (Details)

Rights Plan (Details)	Jul. 25, 2022 $ / shares shares	Sep. 30, 2022 $ / shares	Dec. 31, 2021 $ / shares
Right
Preferred stock, par value (in dollars per share)		$ 0.0001	$ 0.0001
Series A Junior Participating Preferred Stock
Right
Preferred stock, par value (in dollars per share)	$ 0.0001
Preferred Share Purchase Right
Right
Dividend declared in preferred share purchase rights per common share outstanding	1
Exercise price (in dollars per share)	$ 26
Preferred Share Purchase Right | Series A Junior Participating Preferred Stock
Right
Number of shares of stock per each right | shares	0.001